CINXE.COM

<!DOCTYPE html><html lang="en" class="h-100"><head><meta charset="utf-8"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title> University of California Health Solid Tumor Clinical Trials for 2025 — California</title><meta property="og:title" content="University of California Health Solid Tumor Clinical Trials — California"><meta name="description" content="Do you qualify for these Solid Tumor studies? We offer 169 options."><meta property="og:description" content="Do you qualify for these Solid Tumor studies? We offer 169 options."><meta property="og:url" content="https://clinicaltrials.ucbraid.org/solid-tumor"><link rel="canonical" href="https://clinicaltrials.ucbraid.org/solid-tumor"><meta name="author" content="University of California Health"><meta name="generator" content="edu.ucsf.ctsi.rt.trialfinder"><meta name="referrer" content="origin-when-cross-origin"><meta name="google-site-verification" content="UTQ9rwZMafn66BKfZ97YetmUPcYNDdDiV01qhvzc8lk"><meta name="msvalidate.01" content="4E5209CC6688B86BBDD2FE074176C029"><link rel="shortcut icon" href="https://clinicaltrials.ucbraid.org/assets/local/uchealth/img/favicon.png"><link rel="alternate" type="application/atom+xml" title="University of California Health Clinical Trials" href="https://clinicaltrials.ucbraid.org/meta/feed.atom"><meta property="og:type" content="website"><meta name="twitter:card" content="summary"><meta name="twitter:site" content="@UofCalifornia"><meta property="og:image" content="https://clinicaltrials.ucbraid.org/assets/local/uchealth/img/hero.jpg"> <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@4.4.1/dist/css/bootstrap.min.css" integrity="sha256-L/W5Wfqfa0sdBNIKN9cG6QA5F2qx4qICmU2VgLruv9Y=" crossorigin="anonymous"><link rel="stylesheet" href="https://cdn.jsdelivr.net/gh/coliff/bootstrap-rfs@4.3.1/bootstrap-rfs.css" media="screen and (max-width: 1200px)" integrity="sha256-DgOE2c1ekD0TaTyiCQuH2NdeiZ6VifYJdLdfDwq6C+U=" crossorigin="anonymous"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/animate.css@3.7.2/animate.min.css" integrity="sha256-PHcOkPmOshsMBC+vtJdVr5Mwb7r0LkSVJPlPrp/IMpU=" crossorigin="anonymous"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/font-awesome@4.7.0/css/font-awesome.min.css" integrity="sha256-eZrrJcwDc/3uDhsdt61sL2oOBY362qM3lon1gyExkL0=" crossorigin="anonymous"><link rel="stylesheet" href="https://clinicaltrials.ucbraid.org/assets/css/style.css"><link rel="stylesheet" href="https://clinicaltrials.ucbraid.org/assets/local/uchealth/css/style-local.css"> <script src="https://polyfill-fastly.io/v3/polyfill.min.js?features=default%2CObject.assign%2CObject.entries%2CPromise%2CURLSearchParams%2CURL" crossorigin="anonymous" defer></script> <script src="https://cdn.jsdelivr.net/jquery/2.2.4/jquery.min.js" integrity="sha256-BbhdlvQf/xTY9gja0Dq3HiwQF8LaCRTXxZKRutelT44=" crossorigin="anonymous" defer></script><script src="https://cdn.jsdelivr.net/npm/bootstrap@4.4.1/dist/js/bootstrap.bundle.min.js" integrity="sha256-OUFW7hFO0/r5aEGTQOz9F/aXQOt+TwqI1Z4fbVvww04=" crossorigin="anonymous" defer></script> <link rel="dns-prefetch" href="https://www.google.com/"> <script src="https://clinicaltrials.ucbraid.org/assets/js/app.js" defer></script><script>var google_analytics_live_mode=0;var google_analytics_id='UA-1142388-32';var google_analytics_hostname='clinicaltrials.ucbraid.org';if(google_analytics_id&&google_analytics_hostname&&window.location&&window.location.hostname&&window.location.hostname===google_analytics_hostname){google_analytics_live_mode=1}var google_analytics_js_url='https://www.google-analytics.com/analytics_debug.js';if(google_analytics_live_mode){google_analytics_js_url='https://www.google-analytics.com/analytics.js'}(function(c,h,e,b,f,a,d){c['GoogleAnalyticsObject']=f;c[f]=c[f]||function(){(c[f].q=c[f].q||[]).push(arguments)},c[f].l=1*new Date();a=h.createElement(e),d=h.getElementsByTagName(e)[0];a.async=1;a.src=b;d.parentNode.insertBefore(a,d)})(window,document,'script',google_analytics_js_url,'ga');if(!google_analytics_live_mode){}if(google_analytics_live_mode){ga('create',google_analytics_id,'auto')}else{ga('set','sendHitTask',null)}ga('require','outboundLinkTracker');ga('require','pageVisibilityTracker');ga('send','pageview');var s_opt={};s_opt['s_apid']='53G5XLK75T';s_opt['s_ixnm']='trials_uchealth';s_opt['s_ixky']='6e038166fd15da69c2ed075975c00816';s_opt['s_plac']=undefined;s_opt['s_mlti']=true;var _paq=window._paq=window._paq||[];_paq.push(['setTrackerUrl','https://clinicaltrials.ucbraid.org/action/t/l/']);_paq.push(['setSiteId','12']);_paq.push(['setCustomDimension',1,'condition\u002dpage']);_paq.push(['trackPageView']);_paq.push(['enableLinkTracking']);_paq.push(['enableHeartBeatTimer']);(function(){var a=document,g=a.createElement('script'),s=a.getElementsByTagName('script')[0];g.type='text/javascript';g.async=true;g.src='https://clinicaltrials.ucbraid.org/action/t/js/';s.parentNode.insertBefore(g,s)})();</script><script async src="https://cdn.jsdelivr.net/npm/autotrack@1.0.3/autotrack.js" integrity="sha256-MFv0PQKCj7HPlACiJTgQ+3rHnOSY1a510jcQGGwtemQ=" crossorigin="anonymous"></script><script type="application/ld+json"> { "@context": "https://schema.org/", "@type": "WebSite", "publisher": { "@type": "MedicalOrganization", "name": "University of California Health", "address": "California", "url": "https://www.ucop.edu/uc-health/", "logo": "https://s2.googleusercontent.com/s2/favicons?domain_url=https%3A%2F%2Fwww.ucop.edu%2Fuc-health%2F", "sameAs": [ "https://twitter.com/@UofCalifornia" ] } } </script></head><body class="condition-page bg-light d-flex flex-column"> <a id="skip-to-main-content" class="sr-only sr-only-focusable" href="#content">Skip to main content</a> <header id="header" class="mb-4"><div id="uchealth-top-header" style="background: white" class="container-fluid" data-nosnippet><div class="row align-items-center"><div id="uchealth-wordmark-container" class="col-xl-2 col-md-3 col-12"> <a href="https://health.universityofcalifornia.edu/"> <img src="https://clinicaltrials.ucbraid.org/assets/local/uchealth/img/uchealth-wordmark-transparent.png" id="uchealth-wordmark" alt="University of California Health"> </a> </div><div id="uchealth-top-header-links" class="col-xl-10 col-md-9 d-md-block d-none text-right"> <a href="https://health.universityofcalifornia.edu/patient-care/cancer-consortium">Cancer Consortium</a> <a href="https://health.universityofcalifornia.edu/patient-care/cardiac-surgery-consortium">Cardiac Surgery Consortium</a> <a href="https://health.universityofcalifornia.edu/research">Research at UCH</a> <a href="https://www.ucbraid.org/"><span class="font-weight-light">Powered by</span> <span class="font-weight-bold">UC BRAID</span></a> </div></div></div><nav class="navbar navbar-expand-md navbar-light d-print"> <a class="navbar-brand" href="https://clinicaltrials.ucbraid.org/"> <img src="https://clinicaltrials.ucbraid.org/assets/local/uchealth/img/site-name.png" alt="University of California Health Clinical Trials"> </a> <button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbar--menu--primary-content" aria-controls="navbar--menu--primary-content" aria-expanded="false" aria-label="Toggle navigation"> <span class="navbar-toggler-icon"></span> </button> <div class="collapse navbar-collapse justify-content-end" id="navbar--menu--primary-content"><ul class="navbar-nav"> <li class="nav-item" id="navbar--menu--home"> <a class="nav-link" href="https://clinicaltrials.ucbraid.org/">Search</a> </li> <li class="nav-item dropdown"> <a class="nav-link dropdown-toggle" href="https://clinicaltrials.ucbraid.org/browse/" id="navbar--menu--browse-dropdown-link" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> Browse </a> <div class="dropdown-menu dropdown-menu-right" aria-labelledby="navbar--menu--browse-dropdown-link"> <a class="dropdown-item" href="https://clinicaltrials.ucbraid.org/browse/">All trials</a> <div class="dropdown-divider"></div><div class="dropdown-header">Trials for…</div> <a class="dropdown-item" href="https://clinicaltrials.ucbraid.org/browse/healthy">Healthy volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucbraid.org/browse/pediatric" title="Pediatric clinical trials, for people under age 18">People under 18</a> <a class="dropdown-item" href="https://clinicaltrials.ucbraid.org/browse/geriatric" title="Geriatric clinical trials, for people over age 65">People over 65</a> </div></li> <li class="nav-item dropdown"> <a class="nav-link dropdown-toggle" href="https://clinicaltrials.ucbraid.org/about/" id="navbar--menu--about-dropdown-link" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> About <span class="d-none d-lg-inline">the site</span> </a> <div class="dropdown-menu dropdown-menu-right" aria-labelledby="navbar--menu--about-dropdown-link"> <a class="dropdown-item" href="https://clinicaltrials.ucbraid.org/about/">About University of California Health Clinical Trials</a> </div></li></ul></div> </nav><nav class="breadcrumb-and-search-bar navbar navbar-expand navbar-light d-print d-flex justify-content-between"> <div><ol class="breadcrumb navbar-text my-0 pl-1" itemscope="itemscope" itemtype="https://schema.org/BreadcrumbList"><li itemprop="itemListElement" itemscope itemtype="https://schema.org/ListItem"> <a href="https://clinicaltrials.ucbraid.org/" itemscope="itemscope" itemprop="item" itemtype="https://schema.org/Thing" id="navbar--breadcrumb--link-1"> Home <meta itemprop="name" content="University of California Health Clinical Trials"> </a> <meta itemprop="position" content="1"></li><li class="active">Solid Tumor Studies</li></ol></div> <div><div class="d-none d-md-block navbar-text"><form method="GET" action="https://clinicaltrials.ucbraid.org/" class="form-inline my-1" role="search"> <label class="sr-only" for="header-search--input">Search</label> <input id="header-search--input" name="q" type="text" class="form-control form-control-sm" placeholder="Search University of California Health clinical trials" title="Search clinical trials at University of California Health"> <input class="sr-only form-control-sm btn btn-sm btn-secondary" type="submit" value="Search trials"> </form></div></div> </nav></header><main id="content" class="mx-1 mx-md-0"> <div class="container-md" itemscope itemtype="https://schema.org/WebPage"><div id="condition-header"><h1 class="mb-2" itemprop="headline"> <strong>Solid Tumor</strong> clinical trials at University of California Health </h1><p class="h3 mb-5 text-muted" id="condition-header--clinical-trial-counts"><span> 314 in progress, 169 open to eligible people </span></p></div><div class="row"> <div class="col col-xs-12 col-lg-10 "> <div class="trials-list--filter-container card bg-light text-center mb-3 d-none d-print-none" data-nosnippet><div class="card-body p-1"><span class="trials-list--filter-main-heading d-none d-md-inline"> Showing <span class="trials-list--number-of-trials-shown" aria-live="assertive"></span> trials for </span><div class="btn-group btn-group-sm btn-group-toggle ml-3" role="group" aria-label="Filter trials by sex/gender" data-toggle="buttons"> <label class="btn btn-light mr-1 active"> <input checked type="radio" name="trials-list--filter-sex" data-class-wanted=""> <i class="fa fa-male d-none d-lg-inline" aria-hidden="true"></i><i class="fa fa-female d-none d-lg-inline" aria-hidden="true"></i> All </label> <label class="btn btn-light mr-1"> <input type="radio" name="trials-list--filter-sex" data-class-wanted="trials-list--trial-open-to-sex-female"> <i class="fa fa-female d-none d-lg-inline" aria-hidden="true"></i> Female </label> <label class="btn btn-light mr-1"> <input type="radio" name="trials-list--filter-sex" data-class-wanted="trials-list--trial-open-to-sex-male"> <i class="fa fa-male d-none d-lg-inline" aria-hidden="true"></i> Male </label> </div><div class="btn-group btn-group-sm btn-group-toggle ml-3" role="group" aria-label="Filter trials by age range" data-toggle="buttons"> <label class="btn btn-light active"><input checked type="radio" name="trials-list--filter-age" data-class-wanted="">All ages</label> <label class="btn btn-light"><input type="radio" name="trials-list--filter-age" data-class-wanted="trials-list--trial-open-to-age-under-18">Under 18</label> <label class="btn btn-light"><input type="radio" name="trials-list--filter-age" data-class-wanted="trials-list--trial-open-to-age-18-and-over">Over 18</label> </div></div></div> <ul class="list-unstyled" id="trials-list"><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04927663" class="stretched-link">11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible males ages 18 years and up </p><div class="trials-list--trial-summary"><p>This phase I trial studies if positron emission tomography (PET) imaging using 11C-YJH08 can be useful for detecting certain cell receptor expression in tumor cells in patients with cancer that has spread to other parts of the body (metastatic). 11C-YJH08 is a small-molecule radiotracer that binds to receptors on cells (glucocorticoid receptor) so that they show up better on the PET scan. Systemic therapy (including enzalutamide) can cause more glucocorticoid receptors to be produced in tumor cells, which can make the tumor cells resist hormone therapies. If researchers can find a better way to detect whether glucocorticoid receptors are increasing during therapy, it may lead to more successful therapies using glucocorticoid receptor antagonists.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05888532" class="stretched-link">64Cu-GRIP B in Patients With Advanced Malignancies</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This phase I/II clinical trial evaluates if using a radiotracer targeting granzyme B, 64-copper granzyme targeting restricted interaction peptide specific to family member B (64 Cu-GRIP B) with positron emission tomography (PET) imaging can be safe and useful for detecting granzyme B (GrB) in patients with advanced cancers that has spread to nearby tissue or lymph nodes (advanced). Granzyme B (GrB) is a biomarker produced by immune cells in response to immunotherapy, which may highlight tumors that are more likely to respond to treatment. The study population is focused on genitourinary (GU) malignancies, including renal cell and urothelial cancer, two tumor types with high mutational burden and tumor infiltrating lymphocytes compared to other tumor types, and have a predictable response rate at the population level to immune checkpoint inhibitors. The information gained from this trial may allow researchers to develop future trials where 64Cu-GRIP B PET may serve as a biomarker to monitor early response to immunomodulatory therapies which are used to stimulate or suppress the immune system and may help the body fight cancer.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05086692" class="stretched-link">Beta-only IL-2 ImmunoTherapY Study</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05708950" class="stretched-link">KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The goal of this clinical trial is to test the safety and efficacy of KVA12123 alone or combined with pembrolizumab in patients with advanced solid tumors. The main questions this study aims to answer are: 1. What is the safety of KVA12123 when administered alone and in combination with pembrolizumab to advanced cancer patients? 2. What is an appropriate dose of KVA12123 to administer alone and in combination with pembrolizumab to advanced cancer patients in future clinical trials? Participants in this trial will be asked to: 1. Visit the clinical site every 1 - 2 weeks. 2. Receive KVA12123 every 2 weeks alone or in combination with pembrolizumab every 6 weeks. 3. Provide blood samples to evaluate drug levels in blood, drug safety and to explore the effects of each drug on the immune system. 4. Undergo scans every 6 weeks to test the effect of treatment on cancer progression. 5. Undergo other study procedures to evaluate drug safety and participant safety including physical exams, heart function tests, etc.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05163028" class="stretched-link">SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS or EGFR mutations to determine the maximum tolerated dose and recommended Phase II dose of HBI-2376 and characterize its pharmacokinetic profile.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05012618" class="stretched-link">LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a Phase 1 dose-escalation and cohort expansion study that will evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of LUNA18 when administered as a single agent or in combination with other anti-cancer drugs in patients with locally advanced or metastatic solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06253130" class="stretched-link">First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18-89 </p><div class="trials-list--trial-summary"><p>This study will evaluate the preliminary efficacy of IMP1734 in patients with recurrent advanced/metastatic breast cancer, ovarian cancer and metastatic castrate resistant prostate cancer (mCRPC) with deleterious/suspected deleterious mutations of select homologous recombination repair (HRR) genes.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05226507" class="stretched-link">NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The purpose of the dose escalation phase is to evaluate the safety profile of escalating doses and dose schedules of NXP800. In the expansion phase the preliminary efficacy in subjects with ARID1a mutated ovarian clear cell and ovarian endometrioid cancers will be estimated.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05536141" class="stretched-link">AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The purpose of this study is to evaluate the safety and tolerability of: - casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and - casdatifan monotherapy and casdatifan in combination with cabozantinib in participants with ccRCC in the dose expansion stage</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05948865" class="stretched-link">CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The goal of this clinical trial is to test CPO301, a type of drug called an antibody drug conjugate in adult patients with advanced or metastatic solid tumors. The main questions it aims to answer are: - To assess the safety and tolerability of CPO301 at increasing doses and determine the dose to be used in the second part of the study (Part A) - To assess the safety and tolerability of CPO301 at the dose determined to be safe and tolerable in Part A in patients with Non-Small Cell Lung Cancer and potentially other tumor types (Part B) - To evaluate how quickly CPO301 is metabolized by the body (pharmacokinetics or PK) - To evaluate if antibodies to the study drug develop (immunogenicity) - To evaluate preliminary efficacy to the drug - To correlate preliminary efficacy with mutations in a biomarker called EGFR Participants will: - Provide written informed consent - Undergo screening tests to ensure they are eligible for study treatment - Attend all required study visits and receive CPO301 by intravenous injection every 3 weeks until the study doctor determines study treatment should be stopped, based on how well a participant is doing on treatment - Be followed for progression every 3 months for up to 2 years</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05240898" class="stretched-link">RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a Phase 1 study to assess the safety and clinical activity of RO7623066 alone and in combination in patients with advanced solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06005740" class="stretched-link">First in Human Study of TORL-4-500 in Patients With Advanced Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer. For Part 1, any advanced or metastatic solid tumor malignancy will be evaluated including, for example, adrenocortical carcinoma (ACC).</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06384807" class="stretched-link">BHV-1510 (Previously PBI-410) in Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06265727" class="stretched-link">CRB-701 in Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein called nectin-4. The main questions it aims to answer are: What is the the safe and effective dose of CRB-701 when used alone? What cancers can be treated effectively with CRB-701? Participants will be asked to attend clinic and be given a intravenous infusion of CRB-701 on its own. They will have blood tests and other assessments to measure whether CRB-701 will have CT or MRI scans to measure the effect on tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05585320" class="stretched-link">IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of IMM-1-104 when administered as monotherapy or in combination with approved agents in participants with RAS-mutated or RAS/MAPK activated advanced or metastatic solid tumors. The dose exploration will identify the candidate recommended Phase 2 dose (RP2D) of IMM-1-104 to further explore the anti-tumor activity of IMM-1-104 as monotherapy and in combination with approved agents in multiple Phase 2a proof-of-concept cohorts in malignancies of interest.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04857372" class="stretched-link">IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18-120 </p><div class="trials-list--trial-summary"><p>The purpose of this study is to characterize the safety and tolerability of IAG933 in patients with mesothelioma, NF2/LATS1/LATS2 mutated tumors and tumors with functional YAP/TAZ fusions and to identify the maximum tolerated dose and/or recommended dose.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05970497" class="stretched-link">Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>KB707-01 is a Phase 1/2, open-label, multicenter, dose escalation and expansion study. The study will evaluate the safety and tolerability of KB707 in adults with locally advanced or metastatic solid tumors who have progressed on standard of care therapy, cannot tolerate standard of care therapy, refused standard of care therapy, or for whom there is no standard of care therapy as well as the safety, tolerability, preliminary efficacy, and immunologic effect of KB707 administered in combination with Opdualag to subjects with unresectable or metastatic melanoma. Subjects in dose escalation (Cohorts 1 through 3) and dose expansion (Cohort 4) will receive intratumoral injections of KB707 approximately every three weeks. Cohorts 1 through 4 are closed to new enrollment. Dose expansion Cohort 5 and Cohort 6 will evaluate subjects with advanced melanoma. Subjects in Cohort 5 will receive intratumoral injections of KB707 biweekly (q2w), delivered in combination with Opdualag (dosed every q4w per prescribing information). Subjects in Cohort 6 will receive intratumoral injections of KB707 biweekly (q2w), delivered in combination with Keytruda (dosed every q6w per prescribing information). All subjects will be treated until disease progression, death, unacceptable toxicity, symptomatic deterioration, achievement of maximal response, subject choice, Investigator decision to discontinue treatment, or the Sponsor determines to terminate the study.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04986865" class="stretched-link">ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05653882" class="stretched-link">AB248 Alone or in Combination with Pembrolizumab in Adult Patients with Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of AB248 as monotherapy OR in combination with pembrolizumab in adult participants with locally advanced or metastatic solid tumors. The study will consist of a dose escalation and a dose expansion stage.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05325866" class="stretched-link">Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18-99 </p><div class="trials-list--trial-summary"><p>The primary objectives of this study are to observe the safety and tolerability of bemarituzumab and to evaluate preliminary antitumor activity.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCSD trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06244771" class="stretched-link">FMC-376 in Participants with KRAS G12C Mutated Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants with advanced solid tumors will be evaluated.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06036121" class="stretched-link">ADRX-0706 in Select Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0706 in patients with select advanced solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05094336" class="stretched-link">AMG 193 in Subjects With Advanced MTAP-null Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18-100 </p><div class="trials-list--trial-summary"><p>The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of AMG 193 alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. The primary objective of Part 3 of this study is to evaluate the efficacy of AMG 193 in adult participants with metastatic or locally advanced MTAP-null solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05498428" class="stretched-link">Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation [SC-CF]) in combination treatment (all cohorts except Cohort 4) and to characterize the safety of amivantamab SC-CF (Cohort 4).</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03474497" class="stretched-link">UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade</a> </h2><p class="h5" id="trials-list--trial-tagline">“This study is being done to test a new therapy for advanced stage solid tumor cancers involving a combination of radiation and injections.”</p><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a phase I/II study that will evaluate the safety and toxicity of this combinatorial approach. Eligible patients >18 years of age with histologically proven metastatic NSCLC, melanoma, RCC, or HNSCC who have failed PD-1 / PD-L1 checkpoint blockade therapy will be enrolled. Patients must have a candidate treatment lesion (subcutaneous, nodal, or visceral) accessible and safe for radiotherapy and serial intralesional injections as specified by the protocol. They must also have at least one target lesion (distinct from treatment lesion and outside of treatment lesion radiation field) evaluable for response by RECIST. This study will consist of a phase I dose escalation using a standard 3+3 design to determine safety and MTD of intralesional IL-2 which will be dose escalated in conjunction with standard fixed doses of RT and Pembrolizumab. At the MTD there will be a phase II dose expansion which will incorporate a simon-two stage design to assess efficacy and safety. Patients will receive pembrolizumab and intralesional IL-2 in combination with hypofractionated radiotherapy.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03611868" class="stretched-link">APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 12 years and up </p><div class="trials-list--trial-summary"><p>This study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-115, an MDM2 inhibitor, either alone or in combination with pembrolizumab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with metastatic melanomas or advanced solid tumors. Our hypothesis is that restoration of the immune response concomitant to inhibition of the MDM2 pathway (which restores p53 functions) may promote cancer cell death, leading to effective anticancer therapy.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05382559" class="stretched-link">ASP3082 in Adults With Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is an open-label study. This means that people in this study and clinic staff will know that they will receive ASP3082. The study aims to check how safe and well-tolerated ASP3082 is for people with advanced solid tumors that have a specific mutation called KRAS G12D. This study will be in 2 parts. In Part 1, different small groups of people will receive lower to higher doses of ASP3082 by itself, or together with cetuximab. Any medical problems will be recorded at each dose. This is done to find suitable doses of ASP3082, by itself or together with cetuximab, to use in Part 2 of the study. The first group will receive the lowest dose of ASP3082. A medical expert panel will check the results from this group and decide if the next group can receive a higher dose of ASP3082. The panel will do this for each group until all groups have received ASP3082 (by itself or together with cetuximab) or until suitable doses have been selected for Part 2. In Part 2, ASP3082 will be given in by itself, or in combination with other chemotherapy agents. Study treatments will be given through a vein. This is called an infusion. Each treatment cycle is 21 or 28 days long. They will continue treatment until: they have medical problems from the treatment they can't tolerate; their cancer gets worse; they start other cancer treatment; or they ask to stop treatment.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06028373" class="stretched-link">ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>ATG-031 study (alias: PERFORM) is a multicenter, open-label, Phase 1 study of ATG-031 in patients with advanced solid tumors or B-NHL. The study design includes a Dose Escalation Phase and a Dose Expansion Phase, and will enroll patients with advanced solid tumors (i.e., preferred tumor types) or relapsed/refractory (R/R) B-NHLs. The study's primary objective is to evaluate the safety and tolerability of ATG-031 and determine the RP2D（Refered Phase II dose） of ATG-031.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06130553" class="stretched-link">AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a first time in human (FTiH) Phase I/IIa, open-label, multi-centre study of AZD3470 in participants with advanced or metastatic solid tumors with MTAP deficiency. The study consists of several study modules, evaluating the safety, tolerability, pharmacokinetic (PK), pharmacodynamics, and preliminary efficacy of AZD3470 as monotherapy or in combination with other anti-cancer agents.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03526835" class="stretched-link">Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansion part of the study. Cohorts of selected solid tumor indications for which there is evidence of EGFR dependency and potential sensitivity to EGFR inhibition will be evaluated including head and neck cancer and metastatic colorectal cancer (mCRC). The study will further assess the safety, tolerability, PK, PD, immunogenicity, and anti-tumor activity of MCLA-158 in monotherapy or in combination with other therapies.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05346484" class="stretched-link">CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is an open-label, dose-escalation, multi-center phase I study evaluating the safety of CF33-hNIS (hNIS - human sodium iodide symporter) administered via two routes of administration, intratumoral (IT) or intravenous (IV), either as a monotherapy or in combination with pembrolizumab in patients with metastatic or advanced solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04420884" class="stretched-link">Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The main aim of this study is to check if people with advanced solid tumors have side effects from dazostinag, and to check how much dazostinag they can receive without getting significant side effects from it when given alone and in combination with pembrolizumab. The study will be conducted in two phases including a dose escalation phase and a dose expansion phase. In the dose escalation phase, escalating doses of dazostinag are being tested alone and in combination with pembrolizumab to treat participants who have advanced or metastatic solid tumors. In the dose expansion phase, dazostinag will be studied with pembrolizumab with or without chemotherapy in participants with untreated metastatic or recurrent, unresectable squamous cell carcinoma of head and neck (SCCHN) and in combination with pembrolizumab in third-line or later recurrent locally advanced or metastatic microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and third-line recurrent locally advanced or metastatic microsatellite stable/mismatch repair proficient (MSS/pMMR) colorectal cancer (CRC).</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05785741" class="stretched-link">DB-1310 in Advanced/Metastatic Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05914116" class="stretched-link">DB-1311 in Advanced/Metastatic Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311 in subjects with advanced solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04423029" class="stretched-link">DF6002 Alone and in Combination With Nivolumab</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The purpose of this study is to evaluate the safety, tolerability, drug-levels, drug-effects and preliminary anti-tumor activity of DF6002 alone and in combination with Nivolumab in participants with advanced solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06157892" class="stretched-link">Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced or metastatic cancer. Participants in this study must have breast cancer or gastric cancer. Participants must have tumors that have HER2 on them. This allows the cancer to grow more quickly or spread faster. There are few treatment options for patients with advanced or metastatic solid tumors that express HER2. This clinical trial uses an experimental drug called disitamab vedotin (DV). Disitamab vedotin is a type of antibody drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. This clinical trial uses a drug called tucatinib, which has been approved to treat cancer in the United States and some other countries. This drug is sold under the brand name TUKYSA®. This study will test how safe and how well DV, with or without tucatinib, is for participants with solid tumors. This study will also test what side effects happen when participants take these drugs. A side effect is anything a drug does to the body besides treating the disease.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04008797" class="stretched-link">E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The primary objective of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s), and to determine the optimal dose of E7386 in combination with lenvatinib in endometrial carcinoma (EC) (for EC Dose Optimization Part only).</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05443126" class="stretched-link">EP0031 in Patients With Advanced RET-altered Malignancies</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The aim of this study is to assess the safety, side effects and effectiveness of EP0031 in patients with advanced RET-altered malignancies</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04565275" class="stretched-link">ICP-192 in Patients With Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a multi-center, open-label, phase I/II clinical study to evaluate ICP-192 in patients with advanced solid tumors and FGFR gene alterations. It consists of two parts: Part I (Phase I), dose escalation and Part II (Phase II), dose expansion.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05614739" class="stretched-link">LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435. LOXO-435 may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene). Participation could last up to 30 months (2.5 years) and possibly longer if the disease does not get worse.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04843709" class="stretched-link">MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The objective of this study is to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of MRG004A in patients with Tissue Factor positive advanced or metastatic solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06218914" class="stretched-link">NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to all eligible people </p><div class="trials-list--trial-summary"><p>Phase I Study of NT-112, an autologous T-cell therapy product genetically engineered to express an HLA-C*08:02-restricted T cell receptor (TCR), targeting KRAS G12D mutant solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05877599" class="stretched-link">NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06521554" class="stretched-link">NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>Phase 1a/1b dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-330, determine the recommended Phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced or metastatic HER2-altered NSCLC. Phase 1a dose escalation is designed to assess the safety and tolerability of NVL-330 and to select the candidate RP2D(s) and, if applicable, the MTD. Phase 1b expansion is designed to further evaluate the overall safety and tolerability of the candidate RP2D(s) of NVL-330 and to determine the RP2D of NVL 330 in patients with advanced or metastatic HER2 mutant NSCLC.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05118789" class="stretched-link">NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 12 years and up </p><div class="trials-list--trial-summary"><p>Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-520, determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ROS1-positive (ROS1+) NSCLC and other advanced ROS1-positive solid tumors. Phase 1 will determine the RP2D and, if applicable, the maximum tolerated dose (MTD) of NVL-520 in patients with advanced ROS1-positive solid tumors. Phase 2 will determine the objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR) of NVL-520 at the RP2D. Secondary objectives will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS), and clinical benefit rate (CBR) of NVL-520 in patients with advanced ROS1-positive NSCLC and other solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05384626" class="stretched-link">NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 12 years and up </p><div class="trials-list--trial-summary"><p>Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-655, determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors. Phase 1 will evaluate the overall safety and tolerability of NVL-655 and will determine the RP2D and, if applicable, the MTD of NVL-655 in patients with advanced ALK+ solid tumors. Phase 2 will determine the objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR) of NVL-655 at the RP2D. Secondary objectives will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS), and clinical benefit rate (CBR) of NVL-655 in patients with advanced ALK-positive NSCLC and other solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05571839" class="stretched-link">PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This study will test the safety of a drug called PF-08046049/SGN-BB228 in participants with melanoma and other solid tumors that are hard to treat or have spread through the body. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. This study will have 3 parts. Parts A and B of the study will find out how much PF-08046049/SGN-BB228 should be given to participants. Part C will use the information from Parts A and B to see if PF-08046049/SGN-BB228 is safe and if it works to treat solid tumor cancers.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05208762" class="stretched-link">PF-08046054/SGN-PDL1V in Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have five parts. Parts A and B of the study will find out how much PF-08046054/SGN- PDL1V should be given to participants. Part C will use the dose found in Parts A and B to find out how safe PF-08046054/SGN-PDL1V is and if it works to treat solid tumor cancers. In Part D and E, participants will be given PF-08046054/SGN-PDL1V with pembrolizumab to find out how safe this combination is and if it works to treat solid tumor cancers.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06560645" class="stretched-link">PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a Phase 1 study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PRT7732 in patients with select advanced or metastatic solid tumors with a SMARCA4 mutation.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03093116" class="stretched-link">Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 12 years and up </p><div class="trials-list--trial-summary"><p>Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction. Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. The secondary objective will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and clinical benefit rate (CBR) of repotrectinib in each expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04094610" class="stretched-link">Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages up to 25 years </p><div class="trials-list--trial-summary"><p>Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations to estimate the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) and select the Pediatric Recommended Phase 2 Dose (RP2D). Phase 2 will determine the anti-tumor activity of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring ROS1 or NTRK1-3 alterations.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05983133" class="stretched-link">SGN-EGFRd2 in Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This study will test the safety of a drug called SGN-EGFRd2 in participants with advanced solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. Participants will have cancer that cannot be removed (unresectable) or has spread through the body (metastatic). This study will have three parts. Parts A and B of the study will find out how much SGN-EGFRd2 should be given to participants. Part C will use the dose found in parts A and B to find out how safe SGN-EGFRd2 is and if it works to treat solid tumor cancers.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05864144" class="stretched-link">SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05070247" class="stretched-link">TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This study is about TAK-500, given either alone or with pembrolizumab, in adults with select locally advanced or metastatic solid tumors. The aims of the study are: - to assess the safety profile of TAK-500 when given alone and when given with pembrolizumab. - to assess the anti-tumor effects of TAK-500, when given alone and when given with pembrolizumab, in adults with locally advanced or metastatic solid tumors. Participants may receive TAK-500 for up to 1 year. Participants may continue with their treatment if they have continuing benefit and if this is approved by their study doctor. Participants who are receiving TAK-500 either alone or with pembrolizumab will continue with their treatment until their disease progresses or until they or their study doctor decide they should stop this treatment.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05576077" class="stretched-link">TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18-70 </p><div class="trials-list--trial-summary"><p>A multicenter trial to investigate TBio-4101, an autologous, neoantigen-selected, tumor-reactive TIL product, in patients with advanced solid malignancies.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04140526" class="stretched-link">PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancers.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05377996" class="stretched-link">XMT-1660 in Participants With Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>A Study of XMT-1660 in Solid Tumors</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05434234" class="stretched-link">YL201 in Patients With Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201 conducted in China and the United States. The study will include 2 parts: a dose escalation part (Part 1) followed by a dose expansion part (Part 2). Part 1 will estimate the MTD/RED(s) in dose escalation cohorts of patients with advanced solid tumors unresponsive to currently available therapies or for whom no standard therapy is available. Part 2 will include patients with selected advanced solid tumor types enrolled at the MTD/RED(s), to better define the safety profile and evaluate the efficacy of YL201.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05907304" class="stretched-link">Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 12-99 </p><div class="trials-list--trial-summary"><p>To evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumors - To evaluate the safety and tolerability of naporafenib administered with trametinib in patients with RAS Q61X solid tumors - To characterize the pharmacokinetic (PK) profile of naporafenib and trametinib when administered to patients with RAS Q61X solid tumors</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05627063" class="stretched-link">ABSK121-NX in Patients With Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is an open-label phase 1 study with expansion. The study will start with a dose escalation of single-agent ABSK121-NX administered in repeated 28-day cycles in patients with advanced solid tumors to evaluate safety and tolerability. The expansion part will investigate oral ABSK121-NX at the recommended dose for expansion (RDE) to further evaluate safety and tolerability among selected tumor types. Preliminary antitumor activity will also be assessed.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04775485" class="stretched-link">DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 6 months to 25 years </p><div class="trials-list--trial-summary"><p>FIREFLY-1 is an ongoing, Phase 2, multi center, open-label study to evaluate the safety and efficacy of oral pan-RAF inhibitor DAY101 in pediatric, adolescent, and young adult patients with recurrent or progressive low-grade glioma or an advanced solid tumor harboring a known RAF alteration.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06179160" class="stretched-link">INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04913285" class="stretched-link">KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05736731" class="stretched-link">A2B530, a Logic-gated CAR T, in Participants with Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The goal of this study is to test A2B530,an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), and other solid tumors that express CEA and have lost HLA-A*02 expression. The main questions this study aims to answer are: - Phase 1: What is the maximum or recommended dose of A2B530 that is safe for patients - Phase 2: Does the recommended dose of A2B530 kill the solid tumor cells and protect the patient's healthy cells Participants will be required to perform study procedures and assessments, and will also receive the following study treatments: - Enrollment and Apheresis in BASECAMP-1 (NCT04981119) - Preconditioning Lymphodepletion (PCLD) Regimen - A2B530 Tmod CAR T cells at the assigned dose</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06051695" class="stretched-link">A2B694, a Logic-gated CAR T, in Participants with Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The goal of this study is to test A2B694, an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express MSLN and have lost HLA-A*02 expression. The main questions this study aims to answer are: Phase 1: What is the recommended dose of A2B694 that is safe for patients Phase 2: Does the recommended dose of A2B694 kill the solid tumor cells and protect the patient's healthy cells Participants will be required to perform study procedures and assessments, and will also receive the following study treatments: Enrollment and Apheresis in BASECAMP-1 (NCT04981119) Preconditioning Lymphodepletion (PCLD) Regimen A2B694 Tmod CAR T cells at the assigned dose</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCSD trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04449874" class="stretched-link">Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06264921" class="stretched-link">NKT3447 for Adults with Advanced/Metastatic Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, and pharmacokinetics (PK) to determine the maximum tolerated dose (MTD) and/or preliminary recommended dose for expansion (RDE) of NKT3447 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and the preliminary antitumor activity of NKT3447 in adult subjects with cyclin E1 (CCNE1) amplified ovarian cancer at the RDEs selected in Dose Escalation and to determine the preliminary recommended phase 2 dose (RP2D).</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04678648" class="stretched-link">RSC-1255 for Treatment of Patients With Advanced Malignancies</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. The purpose of Phase 1a (Dose Escalation) is to confirm the appropriate treatment dose and Phase 1b (Dose Expansion) is to characterize the safety and efficacy of RSC-1255.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04626635" class="stretched-link">Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This study is researching an investigational drug called REGN7075 by itself and in combination with cemiplimab with or without chemotherapy. The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how safe and tolerable REGN7075 is by itself and in combination with cemiplimab (with or without chemotherapy), and to find out what is the best dose of REGN7075 to be given to patients with advanced solid tumors when combined with cemiplimab (with or without chemotherapy). Another aim of the study is to see how effective REGN7075 by itself, or in combination with cemiplimab (with or without chemotherapy), is at treating cancer patients. The study is also looking at: - Side effects that may be experienced by people taking REGN7075 by itself and in combination with cemiplimab with or without chemotherapy - How REGN7075 works in the body by itself and in combination with cemiplimab with or without chemotherapy - How much REGN7075 is present in the blood when given by itself and in combination with cemiplimab with or without chemotherapy - To see if REGN7075 by itself and in combination with cemiplimab with or without chemotherapy works to treat cancer by controlling the proliferation of tumor cells to shrink the tumor</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03991741" class="stretched-link">Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>To determine whether special tumor fighting cells that is taken from participants' tumors and grown in the laboratory and then given back to the participant will fight the participant's cancer when their immune system is suppressed from attacking these special tumor fighting cells. This is called transfer of autologous (they came from you) tumor infiltrating lymphocytes (the cells that have been grown in the laboratory. Participants getting these cell infusions will also be treated with interleukin-2 (IL-2).</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06401356" class="stretched-link">Extension Study for Patients Previously Enrolled in Studies with Pelabresib</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The purpose of this study is: 1. To provide continued pelabresib treatment to patients who have previously received pelabresib in a parent study and continue collecting safety and efficacy information 2. To evaluate the overall survival and leukemia-free survival of patients who discontinued placebo or pelabresib treatment in pelabresib parent studies</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04886804" class="stretched-link">Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The study has 2 parts. The first part is open to adults with different types of advanced cancer (solid tumours with changes in the HER2 gene) for whom previous treatment was not successful. The second part is open to people with non-small cell lung cancer with a specific mutation in the HER2 gene. The purpose of the first study part is to find the highest dose of a medicine called zongertinib the participants can tolerate. Once this dose is found, it will be used in the second study part to test whether zongertinib can make tumours shrink. In this study, zongertinib is given to people for the first time. Participants take zongertinib as tablets once a day or twice a day. The participants are in the study for as long as they benefit from and can tolerate treatment. Study doctors regularly check the participants' health and monitor the tumours. The doctors also take note of any unwanted effects that could have been caused by zongertinib.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04421820" class="stretched-link">BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when compared to normal cells. BOLD-100 will be combined with cytotoxic FOLFOX chemotherapy in this study, with a dose escalation cohort to ensure tolerability and safety, followed by a cohort expansion phase.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03611595" class="stretched-link">Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 2-26 </p><div class="trials-list--trial-summary"><p>This study is being conducted in order to determine the safety, dose-limiting toxicities, and maximum tolerated dose of cabozantinib in combination with 13-cis-retinoic acid in patients with relapsed or refractory solid tumors including tumors of the central nervous system (CNS)</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04870944" class="stretched-link">CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 12 months to 30 years </p><div class="trials-list--trial-summary"><p>This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Drugs, such as CBL0137, block signals passed from one molecule to another inside a cell. Blocking these signals can affect many functions of the cell, including cell division and cell death, and may kill cancer cells.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03682289" class="stretched-link">Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This phase II trial studies how well ceralasertib, am Ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor, works alone or in combination with olaparib or durvalumab in treating participants with renal cell carcinoma (RCC), urothelial carcinoma, all pancreatic cancers, endometrial cancer, and other solid tumors excluding clear cell ovarian cancer that have spread to nearby tissue or lymph nodes or other parts of the body. ATR kinase inhibitor AZD6738 and olaparib or durvalumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not known if giving ATR kinase inhibitor AZD6738 with or without olaparib or durvalumab may work better in treating participants with solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05694715" class="stretched-link">Combination Therapy in Cancers With Mutations in DNA Repair Genes</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The purpose of this phase 1 clinical trials is to determine whether niraparib (a Poly (ADP-ribose) polymerase inhibitor (PARPi)) can be safely combined with irinotecan with manageable toxicity and reasonable efficacy. Emerging evidence suggest that PARPi is an effective therapeutic strategy in a wider subset of solid tumors that may have defective homologous recombination (HR) or DNA repair gene mutations. BReast CAncer gene (BRCA), partner and localizer of BRCA2 (PALB2), and various other DNA repair germline mutations predispose carriers to cancers of the breast, ovaries, pancreas, prostate and melanoma. A number of preclinical studies have demonstrated that PARP inhibitors can work as chemopotentiators. There is significant interest in this combination, and the recommended phase II dose will be used in the upcoming NCI ComboMatch trial.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06625775" class="stretched-link">Expansion of BBO-10203 in Advanced Solid Tumors (BREAKER-101)</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with trastuzumab in patients with advanced solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05270213" class="stretched-link">RBS2418 in Subjects With Advanced, Metastatic Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor immunity by increasing endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) and adenosine triphosphate (ATP levels) and reducing adenosine production in the tumors. RBS2418 has the potential to be an important therapeutic option for subjects both as monotherapy and in combination with checkpoint blockade. This study is an open-label, multi-site Phase 1a/1b study of RBS2418, a selective ENPP1 inhibitor, in combination with pembrolizumab or as a monotherapy in subjects with advanced unresectable, recurrent or metastatic tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSD trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04185883" class="stretched-link">Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18-100 </p><div class="trials-list--trial-summary"><p>To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C mutant advanced solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05103683" class="stretched-link">First in Human Study of TORL-1-23 in Participants With Advanced Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05156866" class="stretched-link">First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-ADC in patients with advanced cancer</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05948826" class="stretched-link">First in Human Study of TORL-3-600 in Participants With Advanced Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-3-600 in patients with advanced cancer</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05103046" class="stretched-link">First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of UCT-03-008 in patients with advanced solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05438329" class="stretched-link">First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1305/BNT325 in subjects with advanced solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05216432" class="stretched-link">First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, catalytic subunit alpha (PIK3CA) mutation in blood and/or tumor per local assessment. The study will evaluate RLY-2608 as a single agent for patients with unresectable or metastatic solid tumors. It will also evaluate RLY-2608 in combination RLY-2608 + fulvestrant and in triple combination RLY-2608 + fulvestrant + CDK4/6 inhibitor (palbociclib or ribociclib) or CDK4 inhibitor (PF-07220060) for patients with HR+ HER2- locally advanced or metastatic breast cancer or endometrial cancer (palbociclib or ribociclib Part 1). The RLY-2608 single agent arm, RLY-2608 + fulvestrant combination arm, and triple combination arms will have 2 parts: a dose escalation (Part 1) and a dose expansion (Part 2).</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06239467" class="stretched-link">First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>OKI-219-101 is a Phase 1a/1b, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of OKI-219 as monotherapy and in combination with fulvestrant or trastuzumab. Phase 1a (Part A) will investigate escalating doses of OKI-219 monotherapy, and Phase 1b will investigate OKI-219 (at a tolerated dose determined in Part A) in combination with standard dose fulvestrant (Part B) or standard dose trastuzumab (Part C). Participants will continue to receive study treatment until disease progression, intolerable toxicity, or other study treatment withdrawal criteria are met.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05768139" class="stretched-link">First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>Study STX-478-101 is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 in participants with advanced solid tumors with P13Ka mutations. Part 1 will evaluate STX-478 as monotherapy in participants with advanced solid tumors. Part 2 will evaluate STX-478 therapy as combination therapy with fulvestrant in participants with hormone receptor positive (HR+) breast cancer. Part 3 will evaluate STX-478 as combination therapy with fulvestrant and a CDK4/6 Inhibitor (either Ribociclib or Palbociclib) in participants with HR+ breast cancer. Each study part will include a 28-day screening period, followed by treatment with STX-478 monotherapy or combination therapy.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05220098" class="stretched-link">First-in-Human Study of TAK-280 in Participants With Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The main aim of this study is to find out the safety, tolerability, and effect of TAK- 280 in participants with unresectable, locally advanced or metastatic cancer who have experienced treatment failure or are intolerant to standard therapies. Participants will be treated with TAK-280 for up to 14 treatment cycles. Each treatment cycle will be 28 days. After the last dose of study drug, participants will be followed up for survival every 12 weeks for a total of 48 weeks.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06130722" class="stretched-link">First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>First-in-Human, Phase I, open-label, multicenter, dose-escalation study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary antitumor activity of FL115 in patients with advanced solid tumors who have progressed or are intolerant to current standard-of-care therapies, including immune check-point inhibitors administered in single-agent or combination use.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04337177" class="stretched-link">Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 1-30 </p><div class="trials-list--trial-summary"><p>A pilot pharmacokinetic trial to determine the safety and efficacy of a flavored, orally administered irinotecan VAL-413 (Orotecan®) given with temozolomide for treatment of recurrent pediatric solid tumors including but not limited to neuroblastoma, rhabdomyosarcoma, Ewing sarcoma, hepatoblastoma and medulloblastoma</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06241456" class="stretched-link">FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, with or Without Monoclonal Antibodies in Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy following chemotherapy in participants with advanced human epidermal growth factor receptor 2 (HER2)-positive or other advanced solid tumors. The study will consist of a dose-escalation stage, followed by an expansion stage to further evaluate the safety and activity of FT825 in indication-specific cohorts.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04119024" class="stretched-link">Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18-70 </p><div class="trials-list--trial-summary"><p>This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of patients with stage IIIC or IV melanoma or solid tumors that have spread to other places in the body (metastatic). The study agent is called IL13Ralpha2 CAR T cells. T cells are a special type of white blood cell (immune cells) that have the ability to kill tumor cells. The T cells are obtained from the patient's own blood, grown in a laboratory, and modified by adding the IL13Ralpha2 CAR gene. The IL13Ralpha2 CAR gene is inserted into T cells with a virus called a lentivirus. The lentivirus allows cells to make the IL13Ralpha2 CAR protein. This CAR has been designed to bind to a protein on the surface of tumor cells called IL13Ralpha2. This study is being done to determine the dose at which the gene-modified immune cells are safe, how long the cells stay in the body, and if the cells are able to attack the cancer.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04485416" class="stretched-link">Eltrombopag in Patients Undergoing Chemotherapy for Malignant Solid Tumors</a> </h2><p class="h5" id="trials-list--trial-tagline">“Pilot Trial of Eltrombopag in Children Undergoing Chemotherapy for Malignant Solid Tumors”</p><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> open to eligible people ages 1-18 </p><div class="trials-list--trial-summary"><p>Primary Objective: To assess safety of eltrombopag in pediatric patients undergoing intensive chemotherapy for malignant solid tumors. Secondary Objectives: To assess the efficacy of eltrombopag in increasing platelet count up to 2 weeks after completion of chemotherapy in pediatric patients undergoing intensive chemotherapy for malignant solid tumors. Hypothesis: The hypothesis is that eltrombopag an oral thrombopoietin receptor agonist will increase the platelet count safely and efficaciously in children having chemotherapy induced thrombocytopenia while on therapy for solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05599048" class="stretched-link">Hyperpolarized 13C Pyruvate as a Biomarker in Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a single center prospective imaging study investigating the utility of hyperpolarized 13C-pyruvate/metabolic MR imaging. The current protocol will serve as a companion imaging biomarker study paired with standard of care (SOC) therapeutics, as well as investigational therapies that participants may be scheduled to receive outside of this protocol.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04621435" class="stretched-link">Imaging of Solid Tumors Using FAP-2286</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a multi-arm prospective trial that evaluates the ability of a novel imaging radiolabeled agents to detect metastatic cancer in participants with solid tumors using a gallium 68 (68Ga-) or copper 64 (64Cu-) FAP-2286 tracer. FAP-2286 is a peptidomimetic molecule that that binds to Fibroblast Activation Protein (FAP). FAP is a transmembrane protein expressed on cancer-associated fibroblasts, and has been shown to be present on a number of solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04236414" class="stretched-link">PK of Olaparib in Paediatric Patients With Solid Tumours</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> open to eligible people ages 0-18 </p><div class="trials-list--trial-summary"><p>A study to find out whether olaparib is safe and well tolerated when administered to children and adolescents with solid tumours.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06026410" class="stretched-link">KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyl transferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06232408" class="stretched-link">LIONS (PLK4 Inhibitor in Advanced Solid Tumors)</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 12-100 </p><div class="trials-list--trial-summary"><p>The primary objective of this study is to identify a safe and tolerated dose and schedule of the orally administered PLK4 inhibitor RP-1664. In addition, this study will examine the pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of RP-1664 in advanced solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06103669" class="stretched-link">Locally AblatiVe TherApy in OLigO-pRogressive SOlid TUmorS (VALOROUS)</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in systemic failure or permanent discontinuation of therapy) following locally ablative therapy.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03486873" class="stretched-link">Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase. Each participant will transition to this extension study in one of the following three phases, depending on the study phase they were in at the completion of the parent study. Participants who were in the First Course Phase of study treatment with pembrolizumab or lenvatinib in their parent study will enter the First Course Phase of this study and complete up to 35 doses or more every 3 weeks (Q3W) or 17 doses or more every 6 weeks (Q6W) of study treatment with pembrolizumab or a pembrolizumab-based combination or lenvatinib according to arm assignment. Participants who were in the Follow-up Phase in the parent study (post-treatment or Survival Follow-up Phase) will enter the Survival Follow-up Phase of this study. Participants who were in the Second Course Phase in their parent study will enter Second Course Phase of this study and complete up to 17 doses Q3W or 8 doses Q6W of study treatment with pembrolizumab or a pembrolizumab-based combination according to arm assignment. Any participant originating from a parent trial where crossover to pembrolizumab was permitted upon disease progression may be eligible for 35 doses as Q3W or 17 doses Q6W of pembrolizumab (approximately 2 years), if they progress while on the control arm and pembrolizumab is approved for the indication in the country where the potential eligible crossover participant is being evaluated.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04666688" class="stretched-link">LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab in Patients with Metastatic Solid Tumors</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT02717156" class="stretched-link">Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a multi-cohort single arm phase II/screening trial of the combination of a fusion protein that binds EphrinB2 and blocks interaction with cell surface EphB receptors (sEphB4-HSA) in combination with an anti-PD1 antibody (MK-7435 / Pembrolizumab) for treatment of patients with specific solid tumors. There will be four cohorts in this trial: 1. Cohort A, phase II 2nd line trial of sEphB4-HSA and pembrolizumab for platinum refractory metastatic urothelial carcinoma. 2. Cohort B, phase II 3rd line trial of sEphB4-HSA and pembrolizumab for platinum refractory metastatic urothelial carcinoma. 3. Cohort C, phase II neoadjuvant trial of sEphB4-HSA and pembrolizumab for locally advanced muscle invasive urothelial carcinoma. 4. Cohort D, phase II neoadjuvant trial of sEphB4-HSA and pembrolizumab for locally advanced prostate cancer.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03830918" class="stretched-link">Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This phase Ib/II trial studies the best dose of temozolomide and how well it works with niraparib and atezolizumab in treating patients with solid tumors that have spread to other places in the body (advanced) and extensive-stage small cell lung cancer with a complete or partial response to platinum-based first-line chemotherapy. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Niraparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving temozolomide, niraparib and atezolizumab may work better in treating patients with advanced solid tumors and extensive-stage small cell lung cancer.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05055609" class="stretched-link">Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>TRE-515 is a first-in-class small molecule inhibitor of deoxycytidine kinase (dCK) that is being developed for oral administration in patients with solid tumors. In cancer cells, rapid and upregulated DNA replication creates high replication stress, as such, cancer cells are more susceptible than normal cells to perturbations in nucleotide metabolism by DNA-targeting treatments such as TRE-515. The Primary objective is too determine the safety and maximum tolerability of TRE-515 when administered orally once daily as a single agent. The secondary objective is to establish a recommended phase 2 dose (RP2D), to characterize pharmacokinetics (PK) and pharmacodynamics (PD) of TRE-515 preliminary evaluation of antitumor activity The exploratory objectives are to evaluate the relationship between TRE-515 exposure and plasma deoxynucleoside concentrations of deoxycytidine (dC), evaluate the relationship between TRE-515 exposure and intracellular dCK on-target knockdown as measured by a [18F]-clofarabine (CFA) positron emission tomography (PET) probe and to evaluate the relationship between TRE-515 treatment and dCK gene expression in archived tumor tissue when available</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCSD trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05239143" class="stretched-link">P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>A Phase 1, open label, dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic epithelial derived solid tumors, including but not limited to the tumor types listed below.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04976634" class="stretched-link">Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tumors including hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), endometrial cancer (EC),and esophageal squamous cell carcinoma (ESCC). There is no formal hypothesis testing in this study.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04541108" class="stretched-link">Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a multi-center, open-label Phase 0 Master Protocol designed to study the localized pharmacodynamics (PD) of anti-cancer therapies within the tumor microenvironment (TME) when administered intratumorally in microdose quantities via the CIVO device in patients with surface accessible solid tumors for which there is a scheduled surgical intervention. CIVO stands for Comparative In Vivo Oncology. Multiple substudies will include specified investigational agents and combinations to be evaluated.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03715933" class="stretched-link">INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 12-85 </p><div class="trials-list--trial-summary"><p>This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05585034" class="stretched-link">First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to identify the minimum safe and biologically effective/recommended dose (RD) and schedule for XmAb808.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04868877" class="stretched-link">MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>A phase 1/2 open-label multicenter study will be performed with an initial dose escalation part to determine the MTD and/or the RP2D of MCLA-129 in monotherapy or in combination in patients with NSCLC, HNSCC, GC/GEJ, ESCC, or other solid tumors and who are treatment naïve or have progressed after receiving prior therapy for advanced/metastatic disease.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03785249" class="stretched-link">MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05945823" class="stretched-link">Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a nonrandomized, uncontrolled, open-label, multicenter Phase 2 study to evaluate the efficacy, safety, and tolerability of futibatinib in combination with PD-1 antibody-based SoC therapy in adult patients with solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06105021" class="stretched-link">Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects with Advanced or Metastatic Solid Tumor</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This study is open to adult patients with solid tumors who have a KRAS G12V mutation. This mutation is often found in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC) and other cancers. The study is for patients whose cancer has spread through the body and for whom previous treatments were not successful or treatment does not exist. Patients must also be positive for HLA-A*11:01. The purpose of this study is to find the best dose of AFNT-211 that is safe and can shrink tumors in patients. AFNT-211 is an investigational therapy and this is the first time that AFNT-211 is being administered to patients. AFNT-211 is an autologous T cell product which means that it is made from a patient's own T cells. These cells are engineered and grown to recognize the KRAS G12V protein on the cell surface of cancer cells. AFNT-211 is infused into patients after a short course of lymphodepleting chemotherapy. Patients will frequently visit the study site. The doctors there will regularly check the size of the cancer and the patient's health. They will also take note of any unwanted effects. Patients may continue in this study for as long as they benefit from the treatment.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05639751" class="stretched-link">PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a Phase 1 dose-escalation study of PRT3789, a SMARCA2 degrader, in participants with advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) of PRT3789 monotherapy and in combination with docetaxel, describe any dose limiting toxicities (DLTs), define the dosing schedule, and to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) to be used in subsequent development of PRT3789.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05579366" class="stretched-link">Rinatabart Sesutecan (Rina-S) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06014658" class="stretched-link">& PK of MBRC-101 in Advanced Refractory Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a first-in-human (FIH), open label Phase 1/1b study in patients with advanced metastatic solid tumors refractory to standard treatment. Phase 1 will identify potential optimal biologically relevant doses (OBRD) and the maximum tolerated dose (MTD) of MBRC-101 at one 1 or more dosing regimens. Phase 1b will evaluate the safety and preliminary clinical activity of MBRC-101 at potential OBRDs. Phase 1 and Phase 1b will both characterize single and multiple-dose PK profiles and evaluate incidence and persistence of anti-MBRC-101 Ab.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06160752" class="stretched-link">Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-200 in cancers with FGFR2 activating gene alterations, including unresectable locally advanced/metastatic intrahepatic cholangiocarcinoma and other advanced solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04262466" class="stretched-link">IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of brenetafusp in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06425926" class="stretched-link">GIM-531 in Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary effect through selective inhibition of regulatory T-cells (Tregs).</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04137900" class="stretched-link">Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of TAB004 monotherapy and in combination with toripalimab and to describe the PK profile of toripalimab when administered with TAB004, 2) evaluate antitumor activity of TAB004 monotherapy and in combination with toripalimab; and 3) determine the immunogenicity of TAB004 monotherapy and in combination with toripalimab and to determine the immunogenicity of toripalimab when administered with TAB004. The exploratory objectives are to: 1) evaluate pharmacodynamic effects of TAB004 on its target receptor BTLA, as well as effects on the immune system; 2) evaluate biomarkers that may correlate with activity of TAB004 as monotherapy and in combination with toripalimab; 3) evaluate the utility of BTLA ligand, herpesvirus-entry mediator (HVEM), and additional exploratory biomarkers that could aid in selection of appropriate subjects for TAB004 monotherapy and in combination with toripalimab.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05877430" class="stretched-link">Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>Study CJB-101-01 will be conducted at multiple centers in the USA and Republic of Korea as an open-label safety and preliminary efficacy study of CJRB-101 in combination with pembrolizumab in subjects with selected types of advanced or metastatic cancer. The proposed study intends to address the unmet medical needs of low response rate and refractoriness to immune checkpoint inhibitors typically observed in this subject population by performing assessments of response, dose limiting toxicities, pharmacodynamic, and the effect on microbiome biomarkers at different dose levels of CJRB-101 combined with pembrolizumab.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05098132" class="stretched-link">STK-012 Monotherapy and in Combination Therapy in Patients with Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a first-in-human, phase 1a/1b, multicenter, open-label, dose escalation study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04180371" class="stretched-link">BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This clinical trial is evaluating a drug called BT5528 alone and in combination with nivolumab in participants with advanced solid tumors historically known for expression of EphA2. The main goals of this study are to: - Find the recommended dose(s) of BT5528 that can be given safely to participants alone and in combination with nivolumab - Learn more about the side effects of BT5528 - Learn about how effective BT5528 is for the treatment of ovarian cancer, urothelial/bladder cancer, lung cancer (NSCLC), triple-negative breast cancer, head and neck cancer (HNSCC), and gastric/upper gastrointestinal cancer. - Learn more about BT5528 therapy alone and in combination with nivolumab.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04282044" class="stretched-link">CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This clinical study is an open-label, Phase 1, dose-escalation study to determine the safety, tolerability, and efficacy of the drug product produced by Administering CRX100 alone and in combination with Pembrolizumab in advanced solid malignancies. Patients will be screened and evaluated to determine whether or not they meet stated inclusion criteria. Enrolled subjects will undergo leukapheresis to enable the ex vivo generation of CRX100. Patients with non-small cell lung cancer (NSCLC), ovarian cancer, colorectal cancer, hepatocellular carcinoma (HCC), malignant melanoma (excluding uveal melanoma), gastric cancer, triple negative breast cancer, and osteosarcoma. The study will start with monotherapy dose escalation followed by combination cohorts.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04890613" class="stretched-link">CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients with selected solid tumours and associated mutations for future Phase II trials. The safety and tolerability of CX-5461, preliminary evidence of antitumor effect and the effect of CX-5461 on the Health-Related Quality of Life (HRQoL) will also be evaluated. The study will also evaluate the predictive value of mutational signatures and explore the significance of dynamic changes in ctDNA levels and plasma DNA methylome profiling in this study's exploratory cohort.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05489211" class="stretched-link">Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18-130 </p><div class="trials-list--trial-summary"><p>TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06287463" class="stretched-link">DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a multicenter, Phase 1/2 clinical trial to evaluate DCC-3084 alone or in combination with other cancer therapies in participants with advanced cancers. Module A will enroll participants with advanced/metastatic solid tumors. Additional modules exploring other cancers may be added to the master protocol at a later date. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion).</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04143711" class="stretched-link">DF1001 in Patients with Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>DF1001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase will be a dose escalation phase, enrolling patients with various types of solid tumors that express human epidermal growth factor receptor 2 (HER2). The second phase will include a dose expansion using the best dose selected from the first phase of the study. Multiple cohorts will be opened with eligible patients having either HER2 activated non-small cell lung cancer, hormone receptor (HR) positive HER2 negative metastatic breast cancer, or HER2 positive metastatic breast cancer. DF1001-001 will be administered as monotherapy or in combination; combinations are DF1001 + nivolumab, DF1001 + Nab paclitaxel, and DF1001 + sacituzumab govitecan-hziy.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05597839" class="stretched-link">DF9001 in Patients With Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>DF9001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase will be a dose escalation phase, enrolling patients with various types of solid tumors that express epidermal growth factor receptor (EGFR). The second phase will include a dose expansion using the best dose selected from the first phase of the study. Multiple cohorts will be opened with eligible patients having selected solid tumors (monotherapy and in combination with pembrolizumab).</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05007782" class="stretched-link">GS-1811 Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a first-in-human (FIH) study to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of denikitug (also known as GS-1811) as monotherapy and in combination with zimberelimab in participants with advanced solid tumors. This study will be conducted in 6 parts (Parts A, B, and E: monotherapy, Parts C and D: combination therapy, and Part F for both monotherapy and combination therapy) in participants with advanced solid tumors who have received, been intolerant to, or been ineligible for all treatments known to confer clinical benefit or in participants with select solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05838768" class="stretched-link">HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18-100 </p><div class="trials-list--trial-summary"><p>The main purpose of the study is to evaluate the safety and tolerability of HRO761 and identify the recommended dose(s), i.e., the optimal safe and active dose of HRO761 alone or in combination with pembrolizumab or irinotecan that can be given to patients who have cancers with specific molecular alterations called MSIhi (Microsatellite Instability-high) or dMMR (Mismatch Repair Deficient) that might work best to treat these specific cancer types and to understand how well HRO761 is able to treat those cancers.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03947385" class="stretched-link">IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors. Phase 1 (dose escalation - monotherapy) will assess safety, tolerability and pharmacokinetics of IDE196 via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Phase 1 (dose escalation - binimetib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and binimetinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Phase 1 (dose escalation - crizotinib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and crizotinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Evaluation of safety and efficacy across multiple doses may be explored in the dose optimization part of the study. Crizotinib monotherapy with crossover to combination cohort may be assessed for safety and to show the contribution of each study drug to anti-tumor activity. As of Protocol Amendment 10, Phase 1, Phase 2 dose expansion in IDE196 monotherapy, and Phase 2 dose expansion of IDE196 in combination with binimetinib have been fully enrolled. There were no patients enrolled in the crizotinib monotherapy cohorts.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05783622" class="stretched-link">JANX008 in Subjects with Advanced or Metastatic Solid Tumor Malignancies</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18-100 </p><div class="trials-list--trial-summary"><p>This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic carcinoma expressing EGFR.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05533697" class="stretched-link">mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05546268" class="stretched-link">Oral MRT-2359 in Selected Cancer Patients</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This Phase 1/2, open-label, multicenter study is conducted in patients with previously treated selected solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), high-grade neuroendocrine cancer of any primary site, diffuse large B-cell lymphoma (DLBCL), and tumors with L-MYC or N-MYC amplification. Patients receive escalating doses of a GSPT1 molecular glue degrader MRT-2359 to determine safety, tolerability, maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of MRT-2359. Once the MTD and/or RP2D is identified, additional patients enroll to Phase 2 study, which includes molecular biomarkers stratification or selection, namely expression or amplification of L-MYC and N-MYC genes, hormone receptor positive (HR)-positive, human epidermal growth factor 2 (HER2)-negative breast cancer and prostate cancer.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05315700" class="stretched-link">ORIC-114 in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination with Chemotherapy when administered to patients with advanced solid tumors harboring an EGFR or HER2 alteration.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04606446" class="stretched-link">PF-07248144 in Advanced or Metastatic Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with either fulvestrant or letrozole + palbociclib or with PF-07220060 + fulvestrant</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UCSD trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06162221" class="stretched-link">RAS(ON) Inhibitor Combinations in Patients with Advanced RAS-mutated NSCLC</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with each other. The first three subprotocols include the following: Subprotocol A: RMC-6291 +/- RMC-6236 + SOC Subprotocol B: RMC-6236 + SOC Subprotocol C: RMC-9805 +/- RMC-6236 + SOC</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06445062" class="stretched-link">RAS(ON) Inhibitors in Patients with Gastrointestinal Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current subprotocols include the following: Subprotocol A: RMC-6236 + 5-fluorouracil-based regimens Subprotocol B: RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol C: RMC-6236 + gemcitabine + nab-paclitaxel Subprotocol D: RMC-9805 with or without RMC-6236 + 5-fluorouracil-based regimens Subprotocol E: RMC-9805 with or without RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol F: RMC-9805 with or without RMC-6236 + gemcitabine + nab-paclitaxel</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05379985" class="stretched-link">RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06128551" class="stretched-link">RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C Mutant Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18-125 </p><div class="trials-list--trial-summary"><p>This study is to evaluate the safety, tolerability, and PK profiles of RMC-6291 and RMC-6236 in adults with KRAS G12C-mutated solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSD trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03767348" class="stretched-link">RP1 Monotherapy and RP1 in Combination With Nivolumab</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04429542" class="stretched-link">BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05827614" class="stretched-link">CHK1 Inhibitor BBI-355, an EcDNA-directed Therapy (ecDTx), in Subjects with Tumors with Oncogene Amplifications</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>BBI-355 is an oral, potent, selective checkpoint kinase 1 (or CHK1) small molecule inhibitor in development as an ecDNA (extrachromosomal DNA) directed therapy (ecDTx). This is a first-in-human, open-label, 3-part, Phase 1/2 study to determine the safety profile and identify the maximum tolerated dose and recommended Phase 2 dose of BBI-355 administered as a single agent or in combination with select therapies.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03905148" class="stretched-link">BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a 2-part Phase 1b study of BGB-283 (lifirafenib) and PD-0325901 (mirdametinib) combination in participants with tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05887492" class="stretched-link">TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation. The main question[s] it aims to answer are: - the recommended dose for Phase 2 - to evaluate the safety and tolerability of the combination therapy - to determine the pharmacokinetics of TNG260 - to evaluate the initial antineoplastic activity Participants will receive study treatment until they experience an undesirable side effect, their disease progresses or until they withdraw consent.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05029882" class="stretched-link">Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors. ABBV-400 is an investigational drug being developed for the treatment of advanced solid tumors. Study doctors put the participants in groups called treatment arms. The Recommended Phase 2 dose (RP2D) will be explored. Each treatment arm receives a different dose of ABBV-400. This study will include a dose escalation phase to determine the best dose of ABBV-400, followed by a dose expansion phase to confirm the dose and combination with bevacizumab. Approximately 500 adult participants with NSCLC, gastroesophageal adenocarcinoma/gastroesophagel junction adenocarcinoma (GEA) and colorectal cancer (CRC) or advanced solid tumors, will be enrolled in the study in approximately 7-10 sites in the Dose Escalation phase and 85-95 sites in the Dose Expansion phase worldwide. Dose escalation arms, participants will receive intravenous (IV) escalating doses of ABBV-400 monotherapy. Dose expansion arms, participants in the following advanced solid tumor indications: non-squamous NSCLC with wildtype EGFR-expression (wtEGFR NSCLC) [Part 2i] or mutated EGFR-expression (mutEGFR NSCLC) [Part 2ii], squamous NSCLC [Part 2iii], GEA [Part 3] will receive intravenous (IV) ABBV-400 monotherapy, participants CRC will receive IV ABBV-400 monotherapy in expansion [Part 4], participants MET amplification will receive IV ABBV-400 monotherapy in expansion [Part 5], participants MET mutation will receive IV ABBV-400 monotherapy in expansion [Part 6], participants CRC safety lead in will receive escalating doses of IV ABBV-400 in combination with IV bevacizumab [Part 7a], and participants CRC dose optimization in will the low or high dose of IV ABBV-400 determined in Part 7a in combination with IV bevacizumab or oral trifluridine/tipiracil (TAS-102) tablets [Part 7b]. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06084481" class="stretched-link">Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors. ABBV-400 is an investigational drug being developed for the treatment of advanced solid tumors. Study doctors put the participants in groups called cohorts. Each cohort receives ABBV-400 alone (monotherapy) followed by a safety follow-up period. Approximately 260 adult participants with hepatocellular carcinoma (HCC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancers (BTC), esophageal squamous cell carcinoma (ESCC), triple negative breast cancer (TNBC), hormone receptor+/human epidermal growth factor receptor 2 negative (HER2-) breast cancer (hormone receptor-positive [HR+]/HER2-breast cancer [BC]), head and neck squamous-cell-carcinoma (HNSCC), Platinum Resistant High Grade Epithelial Ovarian Cancer (PROC)/primary peritoneal/fallopian tube cancer, or advanced solid tumors, will be enrolled in the study in approximately 54 sites worldwide. In the each cohorts, participants with the following advanced solid tumor indications: HCC, PDAC, BTC, ESCC, TNBC, HR+/HER2-BC, HNSCC, and PROC/primary peritoneal/fallopian tube cancer will receive intravenous (IV) ABBV-400 monotherapy for up to 2 years during and up to the treatment period with an additional safety follow-up period of up to 2 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03863145" class="stretched-link">Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>Subjects will undergo baseline evaluation and an assessment of extent of disease. Subjects in Part 1 (Dose Escalation) will receive escalating doses of CB-03-10 based on a modified Fibonacci schema using a standard oncology 3+3 study design to define an MTD and a RP2D. Plasma PK samples will be collected at predetermined timepoints for all subjects. Subjects in Part 2 (Dose Expansion) of the study will receive CB-03-10 at the RP2D determined in the Part 1 of the study. The indications included in each group will be determined at the completion of Part 1 of the study by Safety Review Committee (SRC). Subjects will be evaluated weekly initially (for 2 cycles in Part 1 and for 1 cycle in Part 2) and every 2 weeks thereafter. Reassessment of disease will be conducted at Week 8 and every 8 weeks thereafter. Subjects with evidence of response (partial or complete) will be re-evaluated at least 4 weeks later for confirmation.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05687110" class="stretched-link">Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This phase I trial tests the safety, side effects, and best dose of novobiocin in treating cancer patients with alterations in deoxyribonucleic acid (DNA) repair genes. Novobiocin is an antibiotic that blocks the activity of a protein called DNA polymerase theta, which helps repair DNA that has become damaged as cells grow and divide. Cancer cells that cannot repair their damaged DNA die. This medication may help shrink or stabilize cancer with a mutation in DNA repair genes.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05862324" class="stretched-link">TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>TAC01-CLDN18.2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes Claudin 18.2. TAC directs T-cells to the targeted antigen (CLDN 18.2), and once engaged with the target, activates them via the endogenous T cell receptor. This is an open-label, multicenter Phase ½ study that aims to establish safety, maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D), pharmacokinetic profile and efficacy of TAC01-CLDN18.2.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-open-to-healthy trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04919811" class="stretched-link">Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The main purpose of the study is to evaluate safety and efficacy of taletrectinib (also known as AB-106 or DS-6051b) monotherapy in the treatment of advanced NSCLC.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05564377" class="stretched-link">Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to all eligible people </p><div class="trials-list--trial-summary"><p>This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04851119" class="stretched-link">Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 12 months to 30 years </p><div class="trials-list--trial-summary"><p>This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may help stop the growth of tumor cells by blocking the signals passed from one molecule to another inside a cell that tell a cell to grow.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05803382" class="stretched-link">Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with the usual treatment with capecitabine in treating patients with cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable) and that it has progressed on previous standard treatment. ZEN003694 is an inhibitor of a family of proteins called the bromodomain and extra-terminal (BET). It may prevent the growth of tumor cells that over produce BET protein. Capecitabine is in a class of medications called antimetabolites. It is taken up by cancer cells and breaks down into fluorouracil, a substance that kills cancer cells. Giving ZEN003694 in combination with capecitabine may be safe in treating patients with metastatic or unresectable solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04068194" class="stretched-link">Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This phase I/II trial studies the best dose and side effects of peposertib and to see how well it works with avelumab and hypofractionated radiation therapy in treating patients with solid tumors and hepatobiliary malignancies that have spread to other places in the body (advanced/metastatic). Peposertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Giving peposertib in combination with avelumab and hypofractionated radiation therapy may work better than other standard chemotherapy, hormonal, targeted, or immunotherapy medicines available in treating patients with solid tumors and hepatobiliary malignancies.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05327010" class="stretched-link">Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib works to shrink tumors in patients with solid tumors that are unlikely to be cured or controlled with treatment and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Another aim of this study is to find out if, and how, patients' genes influence their response to this specific drug combination. For this part of the study, investigators will run tests using samples of patients' tumor tissue and blood that will be collected during the study. ZEN-3694 is an inhibitor of a family of proteins called the bromodomain and extra-terminal (BET). It may prevent the growth of tumor cells that overproduce BET protein. Talazoparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Genes are pieces of the DNA code that individuals inherit from their parents. Some genes work to protect against cancer by correcting damage that can occur in the DNA when cells divide. BRCA1 and BRCA2 are two examples of these types of genes, and they are called tumor-suppressor genes. For example, if a person has a mutation in a BRCA1/2 gene they have a greatly increased risk of developing breast and ovarian cancer because their cells may no longer be able to completely repair damaged DNA. It is the accumulation of DNA damage which causes a cell to change into a cancerous cell. Other genes are also involved in this process, and these are called DNA damage repair genes. The KRAS mutation is a change in a protein in normal cells. Normally KRAS serves as an information hub for signals in the cell that lead to cell growth, but when there is a mutation in KRAS it signals too much and cells grow without being told to, which causes cancer. Combination therapy with ZEN-3694 and talazoparib may be effective at slowing or stopping tumor growth in patients with advanced cancer.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04704661" class="stretched-link">Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial</a> </h2><p class="h5" id="trials-list--trial-tagline">“Volunteer for the DASH Trial and contribute to discoveries that may improve health care for you, your family, and your community!”</p><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The dose escalation phase of this trial identifies the safety, side effects and best dose of ceralasertib (AZD6738) when given in combination with trastuzumab deruxtecan (DS-8201a) in treating patients with solid tumors that have a change (mutation) in the HER2 gene or protein and have spread to other places in the body (advanced). The dose expansion phase (phase Ib) of this trial compares how colorectal and gastroesophageal cancers with HER2 mutation respond to treatment with a combination of ceralasertib and trastuzumab deruxtecan versus trastuzumab deruxtecan alone. Ceralasertib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Trastuzumab deruxtecan is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called deruxtecan. Trastuzumab attaches to HER2 positive cancer cells in a targeted way and delivers deruxtecan to kill them. Ceralasertib and trastuzumab deruxtecan may be safe, tolerable and effective in treating patients with advanced solid tumors expressing the HER2 protein or gene.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06126276" class="stretched-link">Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This phase II ComboMATCH treatment trial compares the effect of neratinib to the combination of neratinib and palbociclib in treating patients with HER2 positive solid tumors. Neratinib and palbociclib are in a class of medications called kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of tumor cells. Giving neratinib and palbociclib in combination may shrink or stabilize cancers that over-express a specific biomarker called HER2.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05820087" class="stretched-link">HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY)</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 22 years and up </p><div class="trials-list--trial-summary"><p>The purpose of this trial is to evaluate the effectiveness and safety of the HistoSonics Edison System for the destruction of kidney tissue by treating primary solid renal tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05967533" class="stretched-link">Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This phase I clinical trial tests the immune effects of fermented wheat germ in patients with advanced solid tumor cancers who are being treated with standard of care checkpoint inhibitors. Fermented wheat germ is a nutritional supplement that some claim is a "dietary food for special medical purposes for cancer patients" to support them in treatment. There have also been claims that fermented wheat germ is "clinically proven" and "recognized by medical experts" to "enhance oncological treatment" and boost immune response to cancer; however, there are currently no documented therapeutic effects of fermented wheat germ as a nutritional supplement. Checkpoint inhibitors, given as part of standard of care for advanced solid tumors, are a type of immunotherapy that may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. The information gained from this trial may allow researchers to determine if there is any value of giving fermented wheat germ with standard of care checkpoint inhibitors for patients with advanced solid tumor malignancies.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04762641" class="stretched-link">ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a first-in-human Phase 1, single-arm, open-label, multicenter, multiple-dose, dose-escalation and dose-expansion study of ABL503 to evaluate the safety, tolerability, MTD and/or RP2D, PK, immunogenicity, preliminary antitumor activity, and the PD effect of ABL503 in subjects with any progressive locally advanced (unresectable) or metastatic solid tumors who are relapsed or refractory following the last line of treatment and have no available standard of care option. This study includes 3 parts: a dose-escalation part, a dose-expansion part and tumor-expansion part</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03943004" class="stretched-link">DFP-14927 in Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a Phase I, open-label, single-arm, dose escalation study of DFP-14927 intravenous infusion administered to patients with refractory or relapsed solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04896697" class="stretched-link">Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a first-in-human, Phase 1/2, multicenter, open-label study designed to evaluate the safety and tolerability of vilastobart (XTX101) as monotherapy and vilastobart (XTX101) and atezolizumab combination therapy in patients with advanced solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05684965" class="stretched-link">XTX301 in Patients with Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT00736749" class="stretched-link">Patients Who Have Participated in Children's Oncology Group Studies</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to all eligible people </p><div class="trials-list--trial-summary"><p>This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04981119" class="stretched-link">Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Design: This is a non-interventional, observational study to evaluate participants with solid tumors with a high risk of relapse for incurable disease. No interventional therapy will be administered on this study. Some of the information regarding the participant's tumor analysis may be beneficial to management of their disease. Participants that meet all criteria may be enrolled and leukapheresed (blood cells collected). The participant's cells will be processed and stored for potential manufacture of CAR T-cell therapy upon relapse of their cancer.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04142437" class="stretched-link">Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to all eligible people </p><div class="trials-list--trial-summary"><p>In this observational study researcher want to learn more about the effectiveness of drug VITRAKVI (generic name: larotrectinib) and how well the drug is tolerated during routine use in patients with TRK fusion cancer which is locally advanced or spread from the place where it started to other places in the body. TRK fusion cancer is a term used to describe a variety of common and rare cancers that are caused by a change to the NTRK (Neurotrophic Tyrosine Kinase) gene called a fusion. During this fusion, an NTRK gene joins together, or fuses, with a different gene. This joining results in the activation of certain proteins (TRK fusion proteins), which can cause cancer cells to multiply and form a tumor. VITRAKVI is an approved drug that blocks the action of the NTRK gene fusion. This study will enroll adult and paediatric patients suffering from a solid tumor with NTRK gene fusion for whom the decision to treat their disease with VITRAKVI has been made by their treating physicians. During the study, patients' medical information such as treatment information with VITRAKVI, other medication or treatments, changes in disease status and other health signs and symptoms will be collected within the normal medical care by the treating doctor. Participants will be observed over a period from 24 to 60 months.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05252416" class="stretched-link">(VELA) Study of BLU-222 in Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-222, a selective inhibitor of CDK2.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03678883" class="stretched-link">9-ING-41 in Patients with Advanced Cancers</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04670679" class="stretched-link">Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>- To evaluate the safety and tolerability of escalating doses of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies in study participants with advanced or metastatic solid tumors. - To determine the Maximum Tolerated Dose (MTD) and/or recommended dose (RD) of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies. - To characterize the pharmacokinetic (PK) profile of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies. - To evaluate the antitumor activity of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04257110" class="stretched-link">First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is an open-label, first-in-human (FIH), phase 1 dose-escalation and cohort expansion study of BB-1701 in subjects with locally advanced/metastatic HER2 expressing solid tumors. The study consists of 2 parts: dose-escalation (Part 1) and cohort expansion (Part 2). Part 1 consists of dose escalation cohorts for determining the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D). Part 2 consists of expansion cohorts, including but not limited to breast cancer, gastric/gastroesophageal junction cancer, bladder cancer and colon cancer, for exploring 1 or more RP2Ds or schedules for expanding/deepening the information/knowledge about clinical safety, clinical pharmacokinetics and anti-tumor activity.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04478279" class="stretched-link">Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is an open-label, two-part, phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 administered IV in patients with advanced solid tumors. The study consists of two phases: a phase 1 dose escalation/regimen exploration phase and a phase 2 expansion phase.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03600883" class="stretched-link">PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>Evaluate the safety and tolerability of sotorasib in adult subjects with KRAS p.G12C mutant advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with KRAS p.G12C mutant advanced solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UCSD trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT02498613" class="stretched-link">Cediranib in Combination With Olaparib in Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other parts of the body (advanced/metastatic) or cannot be removed by surgery (unresectable), including breast cancer, non-small cell lung cancer, small cell lung cancer, and pancreatic cancer. Cediranib maleate and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may also block the flow of oxygen to the tumor, and may help make the tumor more sensitive to olaparib.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06599502" class="stretched-link">AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not currently recruiting here </p><div class="trials-list--trial-summary"><p>This is a first-in-human, modular, Phase I/IIa, open-label, multi-centre study to assess the safety, tolerability, PK, and preliminary efficacy of AZD0022 monotherapy in combination with other anti-cancer agents in participants with tumours harbouring a KRASG12D mutation.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06436157" class="stretched-link">Genetic Testing Uptake Through Enhanced Oncology Nurse-Led Intervention</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not currently recruiting here </p><div class="trials-list--trial-summary"><p>Genetic factors are a significant determinant of the likelihood of developing various types of cancers. Identification of germline risk can have important implications for both patients and their families. Although estimates vary, pathogenic germline variants can be seen in ~3-17.5% of unselected patients with cancer with important clinical significance. Unfortunately, despite progress in multigene testing and the identification of heritable conditions, genetic counseling and testing (GCT) remains underutilized among cancer patients. Although there are multiple barriers to low testing, initial referral to GCT from the treating oncologist has been noted to be the most significant barrier. Nurse navigation has been shown to improve the timeliness of cancer care and patient outcomes across various cancer types and improve the uptake of genomic testing in cancer patients. Despite proven benefits, community cancer centers often face resource limitations that prevent them from consistently assigning a dedicated nurse navigator to cancer patients. However, community centers universally have oncology nurses who routinely educate patients about their systemic therapies. By enhancing the "therapy education" sessions, the investigators hypothesize that oncology nurses can bridge this gap and potentially identify eligible patients, provide essential education on the importance of genetic testing, and facilitate the referral process. The investigators propose a pilot randomized study to evaluate the potential effectiveness, acceptability, and feasibility of a novel, nurse-led "enhanced education" intervention specifically designed to increase the uptake of GCT in adult cancer patients.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06026254" class="stretched-link">Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a rollover study from parent protocol IMSA101-101 for adult patients with advanced malignancies that were previously receiving IMSA101 and who would continue to receive benefit with study treatment of IMSA101 in combination with an immune checkpoint inhibitor (ICI).</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05199584" class="stretched-link">ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This study employs a 2-stage design that aims to evaluate the efficacy and safety of ENV- 101, a potent Hedgehog (Hh) pathway inhibitor, in patients with refractory advanced solid tumors characterized by loss of function (LOF) mutations in the Patched-1 (PTCH1) gene. Stage 1 of this study will enroll approximately 44 patients randomized between two dose levels. As appropriate, Stage 2 of the study will expand enrollment based on the results of Stage 1.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT02099058" class="stretched-link">(PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-399 as monotherapy and in combination with osimertinib, erlotinib, and nivolumab in participants with advanced solid tumors likely to express c-Met. Enrollment is closed for the monotherapy arms, Arm A, and Arm D.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04564027" class="stretched-link">DNA-damage Response Agents in Molecularly Altered Advanced Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The study is investigating efficacy, safety and tolerability of DNA-damage Response Agents (or Combinations), in participants with advanced/metastatic solid malignancies whose tumours contain molecular alterations</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04939610" class="stretched-link">177Lu-FAP-2286 in Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not currently recruiting here </p><div class="trials-list--trial-summary"><p>Fibroblast activation protein (FAP) is a cell surface protein that is highly expressed on the surface of cancer-associated fibroblasts (CAFs) present in the tumor microenvironment of most epithelial cancers, whereas limited expression of FAP is observed in normal tissues. In some cancers of mesenchymal origin, notably sarcoma and mesothelioma, FAP expression has also been observed on the tumor cells themselves. Given the restricted expression profile, FAP is a promising target for peptide-targeted radionuclide imaging and therapeutic agents. Phase 1 of this study is designed to evaluate the safety and establish the recommended intravenous (IV) Phase 2 dose (RP2D) for [177Lu]Lu FAP 2286 monotherapy in participants with FAP expressing solid tumors. Phase 2 is designed to evaluate the safety and efficacy of [177Lu]Lu FAP 2286 as monotherapy in participants with pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), and breast cancer (BC) and in combination with chemotherapy in participants with untreated PDAC or relapsed NSCLC. Participants in both Phase 1 and 2 will be selected for treatment with [177Lu]Lu FAP 2286 based on [68Ga]Ga FAP 2286 imaging for determining tumor FAP expression.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04238819" class="stretched-link">Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The study's purpose is to see if the drug, abemaciclib, is safe and effective when given with other drugs to kill cancer cells. The study is open to children and young adults with solid tumors, including neuroblastoma, that did not respond or grew during other anti-cancer treatment. For each participant, the study is estimated to last up to 2 years.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04491942" class="stretched-link">Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer</a> </h2><p class="h5" id="trials-list--trial-tagline">“Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”</p><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase I trial identifies the best dose, possible benefits and/or side effects of BAY 1895344 in combination with chemotherapy in treating patients with solid tumors or urothelial cancer that has spread to other places in the body (advanced). BAY 1895344 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cisplatin and gemcitabine are chemotherapy drugs that stop the growth of tumor cells by killing the cells. Combining BAY 1895344 with chemotherapy treatment (cisplatin, or cisplatin and gemcitabine) may be effective for the treatment of advanced solid tumors, including urothelial cancer.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04773782" class="stretched-link">Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a Phase 1/2, multicenter, open-label trial of avapritinib in participants 2 to < 18 years of age with advanced relapsed/refractory (R/R) solid tumors, including central nervous system (CNS) tumors, that harbor a PDGFRA and/or KIT mutation (including non-synonymous point mutations, insertions, and deletions) or amplification, or DMG-H3K27a who have no available curative treatment options. This is a single-arm trial in which all participants will receive avapritinib. The study consists of 2 parts: dose confirmation, safety, and PK (Part 1) and initial efficacy, safety, and PK at the Part 2 recommended dose (Part 2).</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06003231" class="stretched-link">Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This clinical trial is studying advanced or metastatic solid tumors. Once a solid tumor has grown very large in one spot or has spread to other places in the body, it is called advanced or metastatic cancer. Participants in this study must have head and neck squamous cell cancer, non-small cell lung cancer, endometrial cancer, or ovarian cancer. Participants must have tumors that have a marker called HER2. This clinical trial uses an experimental drug called disitamab vedotin (DV). DV is a type of antibody-drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. In this study, all participants will get DV once every 2 weeks. This study is being done to see if DV works to treat different types of solid tumors that express HER2. It will also test how safe the drug is for participants. This trial will also study what side effects happen when participants get the drug. A side effect is anything a drug does to your body besides treating the disease.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04440735" class="stretched-link">DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>Part 1: A first-in-human, open-label, Phase I dose escalation study of DSP107 monotherapy and combination therapy with atezolizumab in patients with advanced solid tumors. Part 2: Preliminary efficacy assessment of DSP107 in combination with atezolizumab in second or third line treatment of non small cell lung cancer. Preliminary efficacy assessment of DSP107 as a single agent or in combination with atezolizumab in third line treatment of colorectal cancer.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT02671435" class="stretched-link">Durvalumab (MEDI4736) and Monalizumab in Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a multicenter, open-label, dose-escalation, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, pharmacokinetic (PK), pharmacodynamics, and immunogenicity of durvalumab (MEDI4736) in combination with monalizumab (IPH2201) in adult participants with selected advanced solid tumors and the combination of durvalumab and monalizumab (IPH2201) standard of care systemic therapy with or without biological agent and monalizumab (IPH2201) with biological agent administered to participants with recurrent or metastatic colorectal cancer (CRC).</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05726864" class="stretched-link">ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a Phase 1/2 study to assess the safety and efficacy of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides 7P]) as adjuvant treatment in subjects with solid tumors with mutated KRAS/NRAS. This study builds on the experience obtained with related product ELI-002 2P, which was studied in protocol ELI-002-001 under IND 26909.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04853017" class="stretched-link">ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides]) as adjuvant treatment of minimal residual disease (MRD) in subjects with KRAS/neuroblastoma ras viral oncogene homolog (NRAS) mutated PDAC or other solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04718675" class="stretched-link">KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>Part 1: Dose Escalation. The primary objective of Part 1 of this study is to evaluate the safety and tolerability of KB-0742 in participants with relapsed or refractory (R/R) solid tumors or non-Hodgkin lymphoma (NHL). Part 2: Cohort Expansion. The primary objective of Part 2 of this study is to further evaluate the safety and tolerability of KB-0742 in defined participant cohorts including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC).</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05241834" class="stretched-link">LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-260. LOXO-260 may be used to treat cancer that has a change in a particular gene (known as the RET gene). Participation could last up to 24 months (2 years) and possibly longer if the disease does not get worse.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05307705" class="stretched-link">LOXO-783 in Patients With Breast Cancer/Other Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-783. LOXO-783 may be used to treat breast cancer and other solid tumors that have a change in a particular gene (known as the PIK3CA gene). Participation could last up to 36 months (3 years) and possibly longer if the disease does not get worse.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06586515" class="stretched-link">LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not currently recruiting here </p><div class="trials-list--trial-summary"><p>The main purpose of this study is to assess safety & tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06561685" class="stretched-link">LY4050784 in Participants With Advanced or Metastatic Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not currently recruiting here </p><div class="trials-list--trial-summary"><p>The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMARCA4) alteration who have previously received, do not qualify for, or are refusing standard of care treatments, or there is no standard therapy available for the disease. The study is conducted in two parts - phase Ia (dose-escalation) and phase Ib (dose-optimization, dose-expansion). The study will last up to approximately 4 years.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05293496" class="stretched-link">MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>Study CP-MGC018-02 is a study of vobramitamab duocarmazine (MGC018) in combination with lorigerlimab (MGD019). The study is designed to characterize safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics, and preliminary antitumor activity. Participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors including, but not limited to, metastatic castration-resistant prostate cancer (mCRPC), melanoma, pancreatic cancer, hepatocellular carcinoma (HCC), ovarian cancer, and renal cell carcinoma (RCC) will be enrolled. Vobramitamab duocarmazine and lorigerlimab are administered separately on Day 1 of every 4-week (28-day) cycle at the assigned dose for each cohort. Participants who do not meet criteria for study drug discontinuation may receive study drugs for up to 2 years. Tumor assessments are performed every 8 weeks (± 7 days) for the initial 6 months on study drugs, then every 12 weeks (± 21 days) until progressive disease (PD). Participants will be followed for safety throughout the study. .</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04492488" class="stretched-link">MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The objective of this study is to assess the safety, efficacy, and pharmacokinetics of MRG002, as well as the immunogenicity as defined by the incidence of anti-drug antibody (ADA) of MRG002 in patients with HER2-positive advanced solid tumors and locally advanced or metastatic gastric/gastroesophageal junction (GEJ) cancer.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSD trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03157128" class="stretched-link">Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04381650" class="stretched-link">TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>TAK-981 is being tested in combination with pembrolizumab to treat participants who have select advanced or metastatic solid tumors. The study aims are to evaluate the safety, tolerability, and preliminary efficacy of TAK-981 in combination with pembrolizumab. Participants will be on this combination treatment for 21-day cycles. They will continue with this treatment for up to 24 months or until participants meet any discontinuation criteria.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06607185" class="stretched-link">Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not currently recruiting here </p><div class="trials-list--trial-summary"><p>The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations. LY4066434 will be given alone or in combination with other treatments. The study will have 2 parts: monotherapy dose escalation and dose optimization. The study is expected to last up to approximately 5 years.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04799054" class="stretched-link">TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>TransCon TLR7/8 Agonist is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors. This Phase 1/2 study will evaluate TransCon TLR7/8 Agonist as monotherapy or in combination with pembrolizumab in dose escalation and dose expansion. Participants will receive intratumoral (IT) injection of TransCon TLR7/8 Agonist every cycle. The primary objectives are to evaluate safety and tolerability, and define the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of TransCon TLR7/8 Agonist alone or in combination with pembrolizumab.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05551117" class="stretched-link">Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>Study CP-MGC018-03 is an open-label, two-part, Phase 2 study. Part 1 of the study will enroll participants with metastatic castration-resistant prostate cancer (mCRPC) previously treated with one prior androgen receptor axis-targeted therapy (ARAT). ARAT includes abiraterone, enzalutamide, or apalutamide. Participants may have received up to 1 prior docetaxel-containing regimen, but no other chemotherapy agents. This part of the study will assess the efficacy and tolerability of vobramitamab duocarmazine (MGC018) in two experimental arms (2.0 mg/kg every 4 weeks [Q4W] and 2.7 mg/kg Q4W) . Approximately 100 participants will be randomized 1:1. Part 2 of the study will enroll participants with locally advanced or metastatic squamous cell carcinoma (SCC) of the anus, melanoma, head and neck squamous cell carcinoma (HNSCC), squamous non-small cell lung carcinoma (NSCLC), and small cell lung carcinoma (SCLC). Participants must have progressive following at least 1 prior line of standard chemotherapy for advanced or metastatic disease. Participants will receive vobramitamab docarmazine at a dose of 2.7 mg/kg every 4 weeks. Up to 200 participants may be enrolled in Part 2. In both parts, vobramitamab duocarmazine will be administered intravenously (IV) in clinic on Day 1 of each 4-week cycle. Vobramitamab duocarmazine will be administered until criteria for treatment discontinuation are met. Participants will undergo regular testing for signs of disease progression using computed tomography (CT) scans, magnetic resonance imaging (MRI), bone scans, and prostate-specific antigen (PSA) blood tests. Routine examinations and blood tests will be performed and evaluated by the study doctor.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03845166" class="stretched-link">XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination with atezolizumab, and in combination with avelumab to subjects with advanced solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT02912949" class="stretched-link">Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion (eNRGy)</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05076552" class="stretched-link">Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The main objective for part 1a of the study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) and to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of oral TACH101 in participants with advanced and metastatic solid tumors. For part 1b, the main objective is the objective response rate (ORR) as assessed by radiographic progression measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04772989" class="stretched-link">AB308 in Combination With AB122 in Participants With Advanced Malignancies</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with zimberelimab (AB122) in participants with advanced malignancies.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04225117" class="stretched-link">Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The primary purpose of this study is to determine the antitumor activity of enfortumab vedotin as measured by confirmed objective response rate (ORR) per RECIST v1.1. This study will also assess other measures of antitumor activity; overall survival (OS); as well as the safety and tolerability of enfortumab vedotin for cohorts 1 to 8 and enfortumab vedotin + pembrolizumab in cohort 9.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05242822" class="stretched-link">KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-3248, an oral small molecule FGFR inhibitor, in adults with advanced tumors harboring FGFR2 and/or FGFR3 gene alterations.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04042116" class="stretched-link">Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> currently not accepting new patients, but might later </p><div class="trials-list--trial-summary"><p>This is an open-label, Phase 1b/2 study to determine the recommended dose of lucitanib in combination with nivolumab in patients with an advanced solid tumor (Phase 1b); followed by evaluation of the safety and efficacy of lucitanib and nivolumab in patients with an advanced gynecological solid tumor (Phase 2) and evaluate the effects of dosing under fasting or fed state (Food Effect)</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06682793" class="stretched-link">A2B395, an Allogeneic Logic-gated CAR T, in Participants with Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not yet accepting patients </p><div class="trials-list--trial-summary"><p>The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), renal cell carcinoma (RCC) and other solid tumors that express EGFR and have lost HLA-A*02 expression. The main questions this study aims to answer are: - Phase 1: What is the recommended dose of A2B395 that is safe for patients - Phase 2: Does the recommended dose of A2B395 kill the solid tumor cells and protect the patient's healthy cells Participants will be required to perform study procedures and assessments, and will also receive the following study treatments: - Enrollment in BASECAMP-1 (NCT04981119) - Preconditioning lymphodepletion (PCLD) regimen - A2B395 Tmod CAR T cells at the assigned dose</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05867121" class="stretched-link">Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The purpose of this study is to evaluate the safety and tolerability of RO7496353 when administered in combination with a checkpoint inhibitor (CPI) with or without standard-of-care (SOC) chemotherapy in participants with locally advanced or metastatic solid tumors such as non-small cell lung cancer (NSCLC), gastric cancer (GC) and pancreatic ductal adenocarcinoma (PDAC). The study will be conducted in 2 stages: an initial safety run-in stage and an expansion stage.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05274451" class="stretched-link">LYL797 in Adults With Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This study will evaluate the safety and tolerability of LYL797, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), platinum-resistant epithelial ovarian cancer/ fallopian tube cancer/ primary peritoneal cancer (Ovarian cancer), or Endometrial cancer. The first part of the study will determine the safe dose for the next part of the study, and will enroll patients with TNBC, NSCLC, Ovarian or Endometrial cancer. The second part of the study will test that dose in additional patients with TNBC, NSCLC, Ovarian or Endometrial cancer.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05573035" class="stretched-link">LYL845 in Adults With Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is an open-label, multi-center, dose-escalation study with expansion cohorts, designed to evaluate the safety and anti-tumor activity of LYL845, an epigenetically reprogrammed tumor infiltrating lymphocyte (TIL) therapy, in participants with relapsed or refractory (R/R) metastatic or locally advanced melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC).</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05462873" class="stretched-link">Intravenous QEQ278 in Patients With Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>To characterize safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of QEQ278 in adult patients with advanced/metastatic non-small cell lung cancer, esophageal squamous cell carcinoma, renal cell carcinoma, and human papilloma virus associated head and neck squamous cell carcinoma.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05262400" class="stretched-link">Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07220060 and PF-07104091) in people with breast cancer. This clinical study consists of 2 parts (part 1 and part 2). In part 1, we are seeking participants who: - Have been diagnosed with Breast Cancer (BC) of either types: - Have HR+, HER2- BC - Refractory HR-positive/HER2-positive BC - Have other solid tumors other than BC In part 2, we are seeking participants who: -Have HR-positive/HER2-negative BC Part 1 will include increasing doses of PF-07220060 with PF-07104091. In part 2, participants will take 1 of 2 study medicine combinations. This will help us decide the highest amount of study medicines that can be safety given to people. All participants in this study will receive PF-07220060 with PF-07104091 by mouth. We will compare participant experiences to help us determine if PF-07220060 with PF-07104091 is safe and effective. Participants will take part in this study for about 2 years. During this time, they will receive the study medicine, an x-ray imaging, and will be observed for safety and effects of the study medicines.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05155332" class="stretched-link">Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not currently recruiting here </p><div class="trials-list--trial-summary"><p>This study is open to adults with different types of advanced cancer (solid tumors) that are accessible for injection and/or biopsy. This is a study for people with a life expectancy of at least 3 months after starting study treatment. The purpose of this study is to find the highest dose of a medicine called BI 1831169 that people with advanced cancer can tolerate when taken with or without a type of antibody called a checkpoint inhibitor (anti-PD-1 antibody). Another purpose is to check whether the study treatment can fight cancer. In this study, BI 1831169 is given to people for the first time. This study has 2 parts. In Part 1, participants get BI 1831169 alone for up to 3 months. In Part 2, participants get BI 1831169 in combination with a checkpoint inhibitor. Participants who take the combination treatment get BI 1831169 for up to 3 months and a checkpoint inhibitor for up to 1 year. BI 1831169 is given as an injection into the tumor, or as an infusion into the vein, or both (injection and infusion). Checkpoint inhibitors are given as an infusion into a vein. Participants get the medicines about every 3 weeks. This is called a treatment cycle. Participants visit the site study site regularly. The number of study visits vary based on the study phase and treatment response. Some visits include an overnight stay. The doctors regularly check the participants' health and monitor the tumors. The doctors also take note of any health problems that could have been caused by the study treatment.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT02576431" class="stretched-link">Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib is a drug that blocks the actions of these NTRK genes in cancer cells and can therefore be used to treat cancer.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT02637687" class="stretched-link">Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The study is being done to test the safety of a cancer drug called larotrectinib in children. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib blocks the actions of these NTRK genes in cancer cells and can therefore be used to treat cancer. The first study part (Phase 1) is done to determine what dose level of larotrectinib is safe for children, how the drug is absorbed and changed by their bodies and how well the cancer responds to the drug. The main purpose of the second study part (Phase 2) is to investigate how well and how long different cancer types respond to the treatment with larotrectininb.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03595059" class="stretched-link">ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>An open-label, dose-escalation (Part 1), dose-expansion (Part 2) study to assess the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-155 alone and in combination with paclitaxel or docetaxel. In Part 1 (dose escalation), participants will receive escalating doses of ABBV-155 monotherapy (Part 1a) or ABBV-155 in combination with paclitaxel or docetaxel (Part 1b). In Part 2 (dose expansion), participants will receive ABBV-155 monotherapy or in combination therapy. The ABBV-155 monotherapy cohort will enroll participants with relapsed or refractory (R/R) small cell lung cancer (SCLC) (Part 2a); the ABBV-155 plus a taxane (paclitaxel or docetaxel) combination cohort will enroll participants with R/R non-small cell lung cancer (NSCLC) and breast cancer (Part 2b).</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06415487" class="stretched-link">ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not currently recruiting here </p><div class="trials-list--trial-summary"><p>ACE2016 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR). The ACE2016-001 study is an open-label, Phase I, first-in-human (FIH) study that aims to evaluate the safety and tolerability, persistency, pharmacodynamics and efficacy of ACE2016 in patients with Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR).</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04330664" class="stretched-link">Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors that have a KRAS G12C mutation.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05725291" class="stretched-link">AMT-116 in Patients With Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not currently recruiting here </p><div class="trials-list--trial-summary"><p>This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-116, in Patients with Advanced Solid Tumors</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04250155" class="stretched-link">XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 alone or in combination with a checkpoint inhibitor treatment in participants with locally advanced or metastatic solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03175224" class="stretched-link">APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not currently recruiting here </p><div class="trials-list--trial-summary"><p>To assess: - efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET - efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resistance with MET amplification and disease progression after documented CR or PR with 1st line EGFR inhibitors (EGFR-I)</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT00477958" class="stretched-link">Assessment Tool for Older Patients With Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>RATIONALE: A study that assesses the ability of older patients to think, learn, remember, make judgments, and carry out daily activities may help doctors plan treatment for older patients with cancer. PURPOSE: This clinical trial is studying an assessment tool in older patients with cancer.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT02862275" class="stretched-link">Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This pilot phase I trial studies the side effects of atezolizumab in treating patients with cancer following adoptive cell transfer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT02595931" class="stretched-link">M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery</a> </h2><p class="h5" id="trials-list--trial-tagline">“Experimental targeted cancer therapy and chemotherapy combination for tumors that have returned, spread, or cannot be removed”</p><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase I trial studies the side effects and best dose of M6620 and irinotecan hydrochloride in treating patients with solid tumors that have spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). M6620 and irinotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03815643" class="stretched-link">Avelumab Program Rollover Study</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The main purpose of this study is to monitor the safety and tolerability of avelumab in participants with solid tumors who continue treatment with avelumab under the same treatment regimen as in the parent avelumab study.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCSD trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT02568267" class="stretched-link">Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04579380" class="stretched-link">Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This trial studies how well tucatinib works for solid tumors that make either more HER2 or a different type of HER2 than usual (HER2 alterations) The solid tumors studied in this trial have either spread to other parts of the body (metastatic) or cannot be removed completely with surgery (unresectable). All participants will get both tucatinib and trastuzumab. People with hormone-receptor positive breast cancer will also get a drug called fulvestrant. The trial will also look at what side effects happen. A side effect is anything a drug does besides treating cancer.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06581432" class="stretched-link">Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not currently recruiting here </p><div class="trials-list--trial-summary"><p>This is a study for people with advanced cancer for whom previous treatment was not successful or no treatment exists. Adults aged 18 and over with advanced cancer with HER2 alterations can join the study. The purpose of this study is to find out whether a medicine called zongertinib helps people with advanced cancers with HER2 alterations. HER2 alterations can cause cancer. Zongertinib inhibits HER2. Participants are put into 10 groups based on the type of advanced cancer and the type of HER2 alterations they have. All participants take one dose of zongertinib. Participants can continue the treatment as long as they benefit from it and can tolerate it. Participants visit the study site regularly. During many of the visits, the doctors check the size of the tumour and whether it has spread to other parts of the body. During all the visits, the doctors check participants' health and take note of any unwanted effects.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03425279" class="stretched-link">CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients with Sarcoma</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The objective of this study is to assess the safety and efficacy of mecbotamab vedotin (BA3011) in solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05059522" class="stretched-link">Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04931823" class="stretched-link">Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a Phase 1, multicenter, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of CPO-100 administered intravenously in cycles of 3 weekly doses with 1 week rest (1 cycle = 4 weeks) in adult patients with advanced solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05462717" class="stretched-link">Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the maximum tolerated dose (MTD), and the recommended Phase 2 dose.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04774952" class="stretched-link">RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of escalating doses of RMC-5552 monotherapy in adult participants with relapsed/refractory solid tumors and to identify the recommended Phase 2 dose (RP2D).</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03739931" class="stretched-link">mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The clinical study will assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03485209" class="stretched-link">Tisotumab Vedotin for Patients With Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumors and what side effects (unwanted effects) may occur. There are seven parts to this study. - In Part A, the treatment will be given to participants every 3 weeks (3-week cycles). - In Part B, participants will receive tisotumab vedotin on Days 1, 8, and 15 every 4-week cycle. - In Part C, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. - In Part D, participants will be given treatment on Day 1 of every 3-week cycle. Participants in Part D will get tisotumab vedotin with either: - Pembrolizumab or, - Pembrolizumab and carboplatin, or - Pembrolizumab and cisplatin - In Part E, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. - In Part F, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part F will get tisotumab vedotin with pembrolizumab. - In Part G, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part G will get tisotumab vedotin with pembrolizumab and carboplatin.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05071209" class="stretched-link">Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase I/II trial tests the safety, best dose, and whether elimusertib works in treating patients with solid tumors that have come back (relapsed) or does not respond to treatment (refractory). Elimusertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03213652" class="stretched-link">Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II Pediatric MATCH treatment trial studies how well ensartinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with ALK or ROS1 genomic alterations that have come back (recurrent) or does not respond to treatment (refractory) and may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Ensartinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03210714" class="stretched-link">Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II Pediatric MATCH trial studies how well erdafitinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with FGFR mutations that have spread to other places in the body and have come back or do not respond to treatment. Erdafitinib may stop the growth of cancer cells with FGFR mutations by blocking some of the enzymes needed for cell growth.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03229200" class="stretched-link">Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> accepting new patients by invitation only </p><div class="trials-list--trial-summary"><p>Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib studies, are still benefitting from treatment with ibrutinib, and have no access to commercial ibrutinib for their underlying disease within their region.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06462794" class="stretched-link">First In Human Study of CX-801 in Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not currently recruiting here </p><div class="trials-list--trial-summary"><p>The purpose of this first-in-human study, CTMX-801-101, is to characterize the safety, tolerability, and antitumor activity of CX-801 as monotherapy and in combination with pembrolizumab in adult participants with advanced solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05159440" class="stretched-link">First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-MAB in patients with advanced cancer</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06603844" class="stretched-link">First-in-human Study of CRB-601-01 to Treat Patients with Advanced Solid Tumor.</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not currently recruiting here </p><div class="trials-list--trial-summary"><p>The purpose of this study is to determine the safety, blood concentrations and treatment effect of CRB-601 in combination with immunotherapy or immune-priming radiotherapy in patients who have advanced solid tumors (cancer) and have exhausted other therapeutic options.CRB-601 targets a protein called avb8 integrin which is expressed by some cancers and not others. This study will focus on tumor types which are know to highly or moderately express this protein. Researchers will evaluate the side effects caused by treatment, levels of CRB-601 in the blood, and the effect on the participant cancer. This will help researchers understand the right dose of CRB-601 to use for treatment and whether it is an effective treatment to combine with standard of care treatments such as immunotherapy. It will also help the researchers understand whether combining CRB-601 with standard-of-care immunotherapy and immune-priming radiotherapy is a safe and effective approach to treat cancer. Participants in the study will receive CRB-601 via an infusion every two weeks either alone or in combination with immunotherapy and immune-priming radiotherapy. For patients receiving the immune-priming radiotherapy they will receive three doses of radiotherapy focused on a single tumor. There will be assessments to check on the participants general health status (including blood tests) and adverse effects. Participants will also receive regular CT or MRI scans to evaluate the effect of CRB-601 on their cancer. Participants will continue to visit the clinic every two weeks while they are receiving benefit from treatment. If their cancer progresses, participants will be asked to continue to be followed-up by the researchers to understand long-term outcomes, even if they receive other treatments.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03401385" class="stretched-link">First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This study is one single group of participants with non-small cell lung cancer (NSCLC) who have not been cured by other treatments. It is the first time the drug has been used in humans. There will be two parts and a sub-study. The primary purpose of the parts are: - Dose Escalation: To investigate the safety and tolerability and to determine the maximum tolerated dose (MTD) and the recommended dose for expansion (RDE) of DS-1062a - Dose Expansion: To investigate the safety and tolerability of DS-1062a in additional solid tumors This study is expected to last approximately 6 years from the time the first participant is enrolled to the time the last subject is off the study. Study sites are located in both the United States and Japan. The number of treatment cycles is not fixed in this study. Participants who continue to benefit from the study treatment may continue, unless: - they withdraw - their disease gets worse - they experience unacceptable side effects. The primary purpose of the sub-study is to compare the effectiveness of steroid versus non-steroid mouthwash as prophylaxis against oral mucositis/stomatitis in participants receiving DS-1062a. The sub-study is a randomized study that will include approximately 76 participants enrolling into the Dose Expansion part.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04189445" class="stretched-link">Futibatinib in Patients With Specific FGFR Aberrations</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The purpose of this study is to evaluate the efficacy and safety of futibatinib in patients with FGFR aberrations in 3 distinct cohorts. Patients will be enrolled into one of 3 cohorts: patients with advanced, metastatic or locally-advanced solid tumors harboring FGFR1-4 rearrangements (excluding primary brain tumors and intrahepatic cholangiocarcinoma [iCCA]); patients with gastric or gastro-esophageal junction (GEJ) cancer harboring FGFR2 amplification; and patients with myeloid or lymphoid neoplasms with FGFR1 rearrangements.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04083599" class="stretched-link">GEN1042 Safety Trial and Anti-tumor Activity in Participants with Malignant Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The goal of this trial is to learn about the antibody GEN1042 when it is used alone and when it is used together with another antibody cancer drug, pembrolizumab (with or without chemotherapy), for treatment of participants with certain types of cancer.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05180474" class="stretched-link">GEN1047 for Solid Tumors - First in Human (FIH) Trial</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The purpose of this trial is to measure the following in participants with solid tumors who receive GEN1047: - The side effects seen with GEN1047 - What the body does with GEN1047 once it is administered - What GEN1047 does to the body once it is administered - How well GEN1047 works against solid tumors The estimated trial duration for an individual participant is 8 months, consisting of a 28-day screening period, an estimated 3 month treatment period (the duration of treatment may vary for each participant), and an estimated 4 month post-treatment follow-up period (the duration of follow-up may vary for each participant). All participants will receive active drug; no one will be given placebo.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05909995" class="stretched-link">Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The purpose of this study is to characterize the safety, tolerability, PK, and efficacy of INCB 99280 in combination with ipilimumab in participants with select solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04195555" class="stretched-link">Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II Pediatric MATCH trial studies how well ivosidenib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have IDH1 genetic alterations (mutations). Ivosidenib may block the growth of cancer cells that have specific genetic changes in an important signaling pathway called the IDH pathway.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04418167" class="stretched-link">JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> currently not accepting new patients, but might later </p><div class="trials-list--trial-summary"><p>This is a Phase 1 study of JSI-1187 as monotherapy and in combination with dabrafenib for the treatment of advanced solid tumors with MAPK pathway mutations, including mutations that cause MAPK pathway hyperactivation.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05047536" class="stretched-link">KZR-261 in Subjects With Advanced Solid Malignancies</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>A first-in-human, open-label, multicenter, Phase 1 study of KZR-261 designed to assess the safety and tolerability, preliminary anti-tumor activity, and pharmacokinetics (PK) of KZR-261, as well as identify the recommended Phase 2 dose (RP2D). The study comprises a Part 1 (Dose Escalation) and a Part 2 (Dose Expansion) in solid organ tumors (melanoma/uveal melanoma, mesothelioma, colorectal cancer, prostate cancer, and "All-Tumors").</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03834961" class="stretched-link">Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II trial studies the side effects and how well larotrectinib works in treating patients with previously untreated TRK fusion solid tumors and TRK fusion acute leukemia that has come back. Larotrectinib may stop the growth of cancer cells with TRK fusions by blocking the TRK enzymes needed for cell growth.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03213704" class="stretched-link">Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II Pediatric MATCH trial studies how well larotrectinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with NTRK fusions that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and have come back (relapased) or does not respond to treatment (refractory). Larotrectinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT02535312" class="stretched-link">Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase I/II trial studies the side effects and the best dose of methoxyamine when given together with cisplatin and pemetrexed disodium and to see how well it works in treating patients with solid tumors or mesothelioma that have spread to other places in the body and usually cannot be cured or controlled with standard treatment (advanced), or mesothelioma that does not respond to pemetrexed disodium and cisplatin or carboplatin (refractory). Methoxyamine may shrink the tumor and may also help cisplatin and pemetrexed disodium work better by making tumor cells more sensitive to the drugs. Drugs used in chemotherapy, such as cisplatin and pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving methoxyamine together with cisplatin and pemetrexed disodium may be a better treatment for solid tumors or mesothelioma than methoxyamine and pemetrexed disodium.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05580770" class="stretched-link">Mirdametinib + BGB-3245 in Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>A Phase 1/2a open-label, multicenter, dose escalation and expansion study of mirdametinib in combination with BGB-3245 in adult participants with histologically confirmed, advanced (American Joint Committee on Cancer (AJCC) Stage III or IV) metastatic or unresectable solid cancer that is refractory to or has progressed during or after at least 1 line of appropriate prior systemic anti-cancer therapy including chemotherapy, immunotherapy, or appropriate targeted therapy, or for which there is no treatment available, or prior standard of care therapy was not tolerated.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05340621" class="stretched-link">NAUTILUS: OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The NAUTILUS study is a Phase 1b/2, multi-center, open-label study in which patients with activating mutations in the RAS pathway (Phase 1b) and patients with NRAS-mutated Melanoma (Phase 2) will be treated with a combination of oral OKI-179 combined with the MEK inhibitor binimetinib.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03212274" class="stretched-link">Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II trial studies how well olaparib works in treating patients with glioma, cholangiocarcinoma, or solid tumors with IDH1 or IDH2 mutations that has spread from where it first started (primary site) to other places in the body (metastatic) and that does not respond to treatment (refractory). Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT01543763" class="stretched-link">Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a open-label non-randomized, dose escalation and expansion Phase Ia/Ib study to determine the safety, tolerability and maximum tolerated dose (MTD) of pazopanib in combination with PCI-24781 in patients with advanced solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03030378" class="stretched-link">Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase I trial studies the side effects and best dose of pembrolizumab and recombinant interleukin-12 in treating patients with solid tumors. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Recombinant interleukin-12 may kill tumor cells by blocking blood flow to the tumor and by stimulating white blood cells to kill tumor cells. Giving pembrolizumab and recombinant interleukin-12 may work better than giving pembrolizumab alone in treating patients with solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT02503423" class="stretched-link">Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is an open-label, dose-escalation Phase 1/2 study to assess the safety of ASTX660, determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and recommended dosing regimen, and to obtain preliminary efficacy, pharmacokinetic (PK), and target engagement data, in subjects with advanced solid tumors or lymphoma for whom standard life-prolonging measures are not available.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04553692" class="stretched-link">Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This study is a first-in-human, Phase 1a/1b, multicenter, open-label study to determine the safety, tolerability, and pharmacokinetics of aplitabart as a single agent and in combination in participants with relapsed and/or refractory solid or hematologic cancers, as well as newly diagnosed cancers, and an open-label, randomized study of aplitabart+FOLFIRI+bevacizumab.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05103358" class="stretched-link">Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04152499" class="stretched-link">Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not currently recruiting here </p><div class="trials-list--trial-summary"><p>A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies. Patient must have historically documented, incurable, locally advanced or metastatic cancer that are refractory to standard therapies of one of the following types: 1. Triple negative breast cancer 2. Epithelial ovarian cancer 3. Non-small cell lung cancer 4. Gastric adenocarcinoma/Gastroesophageal junction adenocarcinoma 5. Small cell lung cancer 6. HR+/ HER2-breast cancer 7. Head and neck squamous cell carcinoma 8. Endometrial carcinoma 9. Urothelial carcinoma</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04526106" class="stretched-link">REFOCUS: a First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with ICC and Other Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a Phase 1/2, open-label, FIH study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDy), and antineoplastic activity of RLY-4008, a potent and highly selective FGFR2 inhibitor, in patients with unresectable or metastatic cholangiocarcinoma (CCA) and other solid tumors. The study consists of 4 parts: a dose escalation (Part 1), a dose expansion (Part 2), and an extension (Part 3) and a rollover (Part 4).</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04650451" class="stretched-link">Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> currently not accepting new patients, but might later </p><div class="trials-list--trial-summary"><p>This is a Phase 1/2, open-label, multicenter, non-randomized study to investigate the safety, tolerability, and clinical activity of HER2-specific dual-switch CAR-T cells, BPX-603, administered with rimiducid to subjects with previously treated, locally advanced or metastatic solid tumors which are HER2 amplified/overexpressed.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05275478" class="stretched-link">TNG908 in Patients With MTAP-deleted Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG908, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 192 participants.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06352359" class="stretched-link">(PK), and Efficacy of ONC 841 in Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not currently recruiting here </p><div class="trials-list--trial-summary"><p>This is a Phase I open label, dose-escalation study of intravenous (IV) infusion of ONC-841 as a single agent in patients with advanced/metastatic solid tumors. The study will evaluate seven dose levels of ONC-841 starting from 0.03 mg/kg to 30 mg/kg.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04999969" class="stretched-link">Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The proposed study is designed to examine the effects of AZD0171 and durvalumab in combination with standard-of-care chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC).</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05225584" class="stretched-link">PK, PD, Clinical Activity of KT-333 in Adult Patients with Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This Phase 1a/1b study will evaluate the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of KT-333 in Adult patients with Relapsed or Refractory (R/R) Lymphomas, Large Granular Lymphocytic Leukemia (LGL-L), T-cell prolymphocytic leukemia (T-PLL), and Solid Tumors. The Phase 1a stage of the study will explore escalating doses of single-agent KT-333. The Phase Ib stage will consist of 4 expansion cohorts to further characterize the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of KT-333 in Peripheral T-cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), LGL-L, and solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04320888" class="stretched-link">Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II pediatric MATCH treatment trial studies how well selpercatinib works in treating patients with solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts of the body (advanced), lymphomas, or histiocytic disorders that have activating RET gene alterations. Selpercatinib may block the growth of cancer cells that have specific genetic changes in an important signaling pathway (called the RET pathway) and may reduce tumor size.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT02188264" class="stretched-link">Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase I/Ib trial studies the side effects and best dose of selumetinib when given together with cyclosporine in treating patients with solid tumors or colorectal cancer that have spread to other places in the body and cannot be cured or controlled with treatment. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as cyclosporine, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Giving selumetinib and cyclosporine may be a better treatment for solid tumors or colorectal cancer.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04291079" class="stretched-link">SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a multi-center, open-label, Phase 1, first-in-human (FIH), dose-escalation, and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of SRK-181 administered alone and in combination with anti-PD-(L)1 therapy in adult patients with locally advanced or metastatic solid tumors. The study is divided into 3 treatment parts (Part A1, Part A2, and Part B) and a Long-Term Extension Phase (LTEP).</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05798611" class="stretched-link">ART0380 in Patients With Biologically Selected Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This interventional study will evaluate the efficacy and safety of ART0380 as monotherapy in patients whose tumors have a biology to predict for sensitivity to inhibition of Ataxia-Telangiectasia Mutated and Rad3-related protein kinase (ATR).</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03520075" class="stretched-link">ASTX029 in Subjects With Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This study is a first-in-human, open-label, multicenter, Phase 1-2 study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of ASTX029 administered orally to subjects with advanced solid malignancies who are not candidates for approved or available therapies.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03645928" class="stretched-link">Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not currently recruiting here </p><div class="trials-list--trial-summary"><p>A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL LN-144 (Lifileucel)/LN-145 in combination with checkpoint inhibitors or TIL LN-144 (Lifileucel)/LN-145/LN-145-S1 as a single agent therapy.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04374877" class="stretched-link">CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not currently recruiting here </p><div class="trials-list--trial-summary"><p>This is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of CHS-388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in patients with solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT02650401" class="stretched-link">Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 gene fusions, and extracranial solid tumors harboring NTRK1/2/3 or ROS1 gene fusions.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05060432" class="stretched-link">EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a multicenter, open-label, phase I/II basket study, evaluating the safety, tolerability, RP2D, pharmacokinetics, pharmacodynamics and antitumor activity of EOS-448 (also known as GSK4428859A or belrestotug) combined with standard of care and/or with investigational therapies in participants with advanced solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04521686" class="stretched-link">LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitrate dehydrogenase 1 (IDH1) arginine 132 (R132)-mutant advanced solid tumors, including but not limited to cholangiocarcinoma, chondrosarcoma, and glioma or isocitrate dehydrogenase 2 (IDH2) arginine 140 (R140) or arginine 172 (R172) mutant cholangiocarcinoma.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03564691" class="stretched-link">MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This study consists of several parts: dose escalation, dose expansion, dose expansion in Chinese participants residing in China, and coformulation. Dose escalation is to evaluate the safety, tolerability, and preliminary efficacy of MK-4830 monotherapy administration (Arms A and B) and in combination with pembrolizumab (Arm C). Dose expansion is to evaluate the objective response rate (ORR) of MK-4830 in combination with pembrolizumab (Arms A-F); evaluate the safety and tolerability of MK-4830 administered in combination with pembrolizumab, carboplatin, and pemetrexed (Arm G) and of MK-4830 administered in combination with pembrolizumab and lenvatinib (Arm H); evaluate the safety, tolerability and ORR of MK-4830 in combination with pembrolizumab plus chemotherapy (Arms I-L); and evaluate the safety and tolerability of MK-4830 in combination with pembrolizumab in Chinese participants from China (Arm M). The coformulation part (Arm N) evaluates the safety and tolerability of MK-4830A (coformulation of MK-4830 800 mg + pembrolizumab 200 mg). There is no formal hypothesis testing in this study.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04913337" class="stretched-link">NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04123366" class="stretched-link">Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The purpose of this study is to assess the efficacy and safety of treatment with olaparib (MK-7339) in combination with pembrolizumab (MK-3475) in adults with previously treated, advanced (metastatic and/or unresectable) Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-positive solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05511844" class="stretched-link">ORM-5029 in Subjects with HER2-Expressing Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a Phase 1 first-in-human study of ORM-5029 in participants with HER2-expressing advanced solid tumors. The study consists of two parts: a Part 1 Dose Escalation and Part 2 Dose Expansion.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03709680" class="stretched-link">Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>A study to learn about safety and find out maximum tolerable dose of palbociclib given in combination with chemotherapy (temozolomide with irinotecan or topotecan with cyclophosphamide) in children, adolescents and young adults with recurrent or refractory solid tumors (phase 1). Neuroblastoma tumor specific cohort to further evaluate antitumor activity of palbociclib in combination with topotecan and cyclophosphamide in children, adolescents, and young adults with recurrent or refractory neuroblastoma. Phase 2 to learn about the efficacy of palbociclib in combination with irinotecan and temozolomide when compared with irinotecan and temozolomide alone in the treatment of children, adolescents, and young adults with recurrent or refractory Ewing sarcoma (EWS).</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04458259" class="stretched-link">PF-07265807 in Participants With Metastatic Solid Tumors.</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>A First-in-Human Pharmacokinetic, Safety, and Tolerability Study of PF-07265807 as Monotherapy and in Combination in Participants with Advanced or Metastatic Solid Tumors</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05718557" class="stretched-link">PYX-106 in Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The primary objective of this study is to determine the recommended dose(s) of PYX-106 in participants with relapsed/refractory solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06040541" class="stretched-link">RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not currently recruiting here </p><div class="trials-list--trial-summary"><p>This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04855656" class="stretched-link">RP-6306 Alone or in Combination with RP-3500 or Debio 0123 in Patients with Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not currently recruiting here </p><div class="trials-list--trial-summary"><p>The primary purpose of this study is to assess the safety and tolerability of RP-6306 alone and in combination with RP-3500 or in combination with Debio 0123 in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05147350" class="stretched-link">RP-6306 with FOLFIRI in Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The primary purpose of this study is to assess the safety and tolerability of RP-6306 with FOLFIRI in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD), identify a recommended phase 2 dose (RP2D) and preferred schedule, and assess preliminary anti-tumor activity.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05147272" class="stretched-link">RP-6306 With Gemcitabine in Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The primary purpose of this study is to assess the safety and tolerability of RP-6306 in combination gemcitabine, in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) of RP-6306 in combination with gemcitabine, identify a recommended phase 2 dose (RP2D) and preferred schedule, examine preliminary pharmacokinetics (PK) and assess anti-tumor activity.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03964727" class="stretched-link">Sacituzumab Govitecan in Participants With Metastatic Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy, in participants with metastatic (cancer that has spread) solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03813615" class="stretched-link">Pre-surgical Aerobic Exercise on Patients With Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The purpose of this study is to find the safest level of aerobic training for people about to undergo surgery for their cancer, and to learn what effects, if any, aerobic exercise has on these patients and the outcomes of their cancers. This part of the study (Phase 0) will evaluate the feasibility and quality of at-home exercise and assessment procedures and find out whether study participants are willing to practice continuous lifestyle monitoring using apps and electronic devices. Phase 1a will compare the effects and feasibility of six different doses of aerobic exercise and will continue evaluating the quality of at-home study procedures, which includes the use of continuous lifestyle monitoring through apps and electronic devices. In order to facilitate completion of the phase 1a component, we will backfill the 90, 225, and 300 mins/wk dosing cohorts with at least 4 patients in each dose cohort.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04900519" class="stretched-link">STI-6643 in Subjects With Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not currently recruiting here </p><div class="trials-list--trial-summary"><p>This is a first-in-human, phase 1, open-label, dose-escalation study of STI-6643 administered by intravenous infusion in subjects with a relapsed/refractory advanced solid tumor.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT02499328" class="stretched-link">MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This multicentre, open-label, Phase 1b/2 study is designed as a 2 part study consisting of a dose-escalation, safety run-in Part A and a dose-expansion Part B</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04585035" class="stretched-link">D-1553 in Subjects With Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a phase 1/2, open label study of D-1553 single agent and combination treatment to assess the safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and antitumor activities in subjects with advanced or metastatic solid tumor with KRasG12C mutation.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06251310" class="stretched-link">SW-682 in Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not currently recruiting here </p><div class="trials-list--trial-summary"><p>This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with or without Hippo pathway alterations that are refractory to, or have progressed, during or after appropriate prior systemic anticancer therapy, including chemotherapy, immunotherapy, radiation therapy or targeted therapy, or for which no treatment is available, or prior standard of care (SOC) therapy was not tolerated and for which there is no further SOC treatment available. The study includes a Part 1 (Phase 1a) dose escalation phase and a Part 2 (Phase 1b) dose expansion to optimize the dose to be used for further development. All participants will self-administer SW-682 by mouth in 28-day cycles.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT02465060" class="stretched-link">Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)</a> </h2><p class="h5" id="trials-list--trial-tagline">“Will identifying genetic abnormalities in tumor cells help doctors plan better, more personalized treatment for cancer patients?”</p><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and does not respond to treatment (refractory). Patients must have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03155620" class="stretched-link">Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03284385" class="stretched-link">Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II trial studies how well adavosertib works in treating patients with SETD2-deficient solid tumors that have spread to other places in the body (advanced/metastatic). Adavosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04514497" class="stretched-link">Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase I trial tests the safety, side effects and best dose of BAY 1895344 when given together with usual chemotherapy (irinotecan or topotecan) in treating patients with solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced), with a specific focus on small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. BAY 1895344 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as irinotecan and topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding BAY 1895344 to irinotecan or topotecan may be safe and tolerable in treating patients with advanced solid tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT01989585" class="stretched-link">Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase I/II trial studies the side effects and best dose of dabrafenib, trametinib, and navitoclax and to see how well they work in treating patients with BRAF mutant melanoma or solid tumors that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Navitoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of tumor cells by blocking Bcl-2, a protein needed for tumor cell survival. Giving navitoclax, dabrafenib, and trametinib may help shrink tumors in patients with melanoma.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05372614" class="stretched-link">Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> currently not accepting new patients, but might later </p><div class="trials-list--trial-summary"><p>This phase I trial tests the safety, side effects, and best dose of neratinib in combination with trastuzumab deruxtecan in treating patients with solid tumors that have spread to other parts of the body (metastatic) or that cannot be removed by surgery (unresectable), and have changes in a gene called human epidermal growth factor receptor 2 (HER2). Neratinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Trastuzumab deruxtecan is in a class of medications called antibody-drug conjugates. It is composed of a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called deruxtecan. Trastuzumab attaches to HER2 positive tumor cells in a targeted way and delivers deruxtecan to kill them. Adding neratinib to trastuzumab deruxtecan may be able to shrink cancer with a change in the HER2 gene.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04284774" class="stretched-link">Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have recurred or spread to other places in the body (advanced), lymphoma, or histiocytic disorders, that have a genetic alteration in the gene HRAS. Tipifarnib may block the growth of cancer cells that have specific genetic changes in a gene called HRAS and may reduce tumor size.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT02909777" class="stretched-link">CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This research study is evaluating a novel drug called CUDC-907 as a possible treatment for resistant (refractory) pediatric solid tumors (including neuroblastoma), lymphoma, or brain tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04969315" class="stretched-link">TT-10 as a Single Agent in Subjects With Advanced Selected Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The purpose of this study is to evaluate the safety and tolerability of orally administered TT-10 in subjects with advanced selected solid tumors. The dose escalation portion of the study will determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of TT-10.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03698994" class="stretched-link">Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II Pediatric MATCH trial studies how well ulixertinib works in treating patients with solid tumors that have spread to other places in the body (advanced), non-Hodgkin lymphoma, or histiocytic disorders that have a genetic alteration (mutation) in a signaling pathway called MAPK. A signaling pathway consists of a group of molecules in a cell that control one or more cell functions. Genes in the MAPK pathway are frequently mutated in many types of cancers. Ulixertinib may stop the growth of cancer cells that have mutations in the MAPK pathway.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT01012817" class="stretched-link">Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase I/II trial studies the side effects and best dose of veliparib and topotecan hydrochloride and to see how well they work in treating patients with solid tumors, ovarian cancer that has come back or does not respond to treatment, or primary peritoneal cancer. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as topotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib with chemotherapy may kill more tumor cells.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT01366144" class="stretched-link">Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase I trial studies the side effects and the best dose of veliparib when given together with paclitaxel and carboplatin in treating patients with solid tumors that are metastatic or cannot be removed by surgery and liver or kidney dysfunction. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib together with paclitaxel and carboplatin may kill more tumor cells.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05052268" class="stretched-link">XTX202 in Patients With Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX202 in Patients with Advanced Solid Tumors</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSD trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03906331" class="stretched-link">Treatment of Cancers With Rearranged During Transfection (RET) Activation</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not accepting new patients </p><div class="trials-list--trial-summary"><p>Expanded access for participants with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an existing clinical trial. The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT02520713" class="stretched-link">iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This research study is evaluating the use of specialized testing of solid tumors including sequencing. The process of performing these specialized tests is called tumor profiling. The tumor profiling may result in identifying changes in genes of the tumor that indicate that a particular therapy may have activity. This is called an individualized cancer therapy (iCat) recommendation. The results of the tumor profiling and, if applicable, the iCat recommendation will be returned.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li></ul><div><p class="text-muted small comma-list"> Our lead scientists for Solid Tumor research studies include <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/pamela.munster" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Pamela Munster</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucla.edu/nicholas.mcandrew" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Nicholas McAndrew, MD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.icts.uci.edu/fachyi.lee" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Fa-Chyi Lee</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/matthew.gubens" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Matthew Gubens</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucla.edu/noah.federman" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Noah Federman</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsd.edu/shumei.kato" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Shumei Kato</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/david.oh" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">David Oh</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucla.edu/antoni.ribas" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Antoni Ribas</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucdavis.edu/anjali.pawar" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Anjali Pawar, MD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucla.edu/aaron.lisberg" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Aaron Lisberg</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/thomas.hope" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Thomas Hope, MD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucla.edu/jonathan.goldman" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Jonathan Goldman, MD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucla.edu/brian.shuch" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Brian Shuch, MD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucdavis.edu/mamta.parikh" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Mamta Parikh, MD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/adil.daud" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Adil Daud, MD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/bridget.keenan" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Bridget Keenan, PhD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/sabine.mueller" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Sabine Mueller</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucdavis.edu/jonathan.riess" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Jonathan Riess, MD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/arpita.desai" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Arpita Desai</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.icts.uci.edu/farshid.dayyani" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Farshid Dayyani</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/amit.sabnis" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Amit Sabnis</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucla.edu/bartosz.chmielowski" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Bartosz Chmielowski</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsd.edu/sandip.patel" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Sandip Patel</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucdavis.edu/marcio.malogolowkin" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Marcio H. Malogolowkin</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/michael.evans" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Michael Evans</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/collin.blakely" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Collin Blakely</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/hyunseok.kang" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Hyunseok Kang</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucdavis.edu/nancy.nguyen" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Nancy T. Nguyen</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsd.edu/peter.zage" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Peter Zage</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.icts.uci.edu/misako.nagasaka" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Misako Nagasaka, MD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsd.edu/gregory.daniels" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Gregory Daniels, MD, PhD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/rahul.aggarwal" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Rahul Aggarwal, MD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucdavis.edu/arnaud.bewley" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Arnaud Bewley, MD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsd.edu/ezra.cohen" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Ezra Cohen, MD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/arun.rangaswami" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Arun A. Rangaswami</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucla.edu/joel.hecht" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Joel Hecht</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/alain.algazi" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Alain Algazi</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucla.edu/zev.wainberg" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Zev A Wainberg</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.icts.uci.edu/sai-hong.ou" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Sai-Hong Ignatius Ou, MD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucla.edu/arun.singh" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Arun Singh</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.icts.uci.edu/jennifer.valerin" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Jennifer B. Valerin</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsd.edu/peter.vu" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Peter Vu, MD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/nicholas.butowski" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Nicholas Butowski</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/robert.bok" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Robert Bok, MD, PhD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/robert.goldsby" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Robert E. Goldsby</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.icts.uci.edu/ritesh.parajuli" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Ritesh Parajuli</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsd.edu/gregory.botta" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Gregory Botta, MD, PhD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucdavis.edu/joseph.tuscano" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Joseph M Tuscano</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucdavis.edu/tianhong.li" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Tianhong Li, MD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/lawrence.fong" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Lawrence Fong</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/hope.rugo" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Hope Rugo</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucla.edu/sven.devos" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Sven De Vos</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucla.edu/deborah.wong" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Deborah Wong</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucdavis.edu/megan.daly" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Megan Daly, MD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucdavis.edu/xiao.zhao" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Xiao Zhao, MD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucla.edu/lee.rosen" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Lee S. Rosen, MD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/kieuhoa.vo" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Kieuhoa T. Vo</span></a></span>. </p><p class="text-muted small">Last updated: <time itemprop="dateModified" datetime="2025-02-06">February 6, 2025</time></p></div></div> </div> </div> </main><footer class="mt-auto" role="contentinfo" data-nosnippet><div style="background: #00324e" class="container-fluid py-3"><div class="row align-items-center"><div class="col-12 col-md-8 text-white"> <a href="https://www.ucbraid.org/" class="d-block d-md-inline-block pr-md-3 "><img src="https://clinicaltrials.ucbraid.org/assets/local/uchealth/img/ucbraid-logo-white-on-transparent.png" style="height: 2em" alt="UC BRAID"></a> <a href="https://health.universityofcalifornia.edu/patient-care/cancer-consortium" class="d-block d-md-inline-block">Cancer Consortium</a> <a href="https://health.universityofcalifornia.edu/patient-care/cardiac-surgery-consortium" class="d-block d-md-inline-block">Cardiac Surgery Consortium</a> <a href="https://health.universityofcalifornia.edu/research" class="d-block d-md-inline-block">Research at University of California Health</a> </div><div class="col-12 col-md-4 text-md-right"> © The Regents of the University of California </div></div></div></footer></body></html>